

FORM PTO-1390 (REV 11-2000)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER <b>3911-8</b>
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>09/869136</b> <i>Unassigned</i>
INTERNATIONAL APPLICATION NO. <b>PCT/NZ99/00228</b>	INTERNATIONAL FILING DATE <b>24 December 1999</b>	PRIORITY DATE CLAIMED <b>24 December 1998</b>

TITLE OF INVENTION

**SUPERANTIGENS**

APPLICANT(S) FOR DO/EO/US

**FRASER et al**

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The U.S. has been elected by the expiration of 19 months from the priority date (Article 31).
5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☒ is attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ has been communicated by the International Bureau.
  - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
- ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
  - a. ☐ is attached hereto.
  - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
- ☐ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
  - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
  - b. ☐ have been communicated by the International Bureau.
  - c. ☐ have not been made; however, the time limit for making such amendments has **NOT** expired.
  - d. ☐ have not been made and will not be made.
- ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
- ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 To 20 below concern document(s) or information included:

11. ☐ An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☐ Other items or information.

15. APPLICATION NO. (If known, see 37 C.F.R. 1.5) <b>04/809136</b>	INTERNATIONAL APPLICATION NO. <b>PCT/NZ99/00228</b>	ATTORNEY'S DOCKET NUMBER <b>3911-8</b>
-----------------------------------------------------------------------	--------------------------------------------------------	-------------------------------------------

21. ☒ The following fees are submitted:


BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):	CALCULATIONS PTO USE ONLY																			
-- Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO .....\$1000.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO .....\$860.00 -- International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO .....\$710.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) .....\$690.00 -- International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) .....\$100.00																				
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$	1000.00																		
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).	\$	130.00																		
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:15%;">CLAIMS</th> <th style="width:15%;">NUMBER FILED</th> <th style="width:15%;">NUMBER EXTRA</th> <th style="width:15%;">RATE</th> <th style="width:15%;"></th> <th style="width:15%;"></th> </tr> <tr> <td>Total Claims</td> <td>30</td> <td>-20 =</td> <td>10</td> <td>X</td> <td>\$18.00</td> </tr> <tr> <td>Independent Claims</td> <td>5</td> <td>-3 =</td> <td>2</td> <td>X</td> <td>\$80.00</td> </tr> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			Total Claims	30	-20 =	10	X	\$18.00	Independent Claims	5	-3 =	2	X	\$80.00	\$	180.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																	
Total Claims	30	-20 =	10	X	\$18.00															
Independent Claims	5	-3 =	2	X	\$80.00															
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)		\$270.00	\$	0.00																
TOTAL OF ABOVE CALCULATIONS =		\$	1470.00																	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.		0.00																		
SUBTOTAL =		\$	1470.00																	
Processing fee of \$130.00, for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).		0.00																		
TOTAL NATIONAL FEE =		\$	1470.00																	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property		0.00																		
Fee for Petition to Revive Unintentionally Abandoned Application (\$1240.00 - Small Entity = \$620.00)		0.00																		
TOTAL FEES ENCLOSED =		\$	1470.00																	
	Amount to be:																			
	refunded	\$																		
	Charged	\$																		

3. ☒ A check in the amount of \$1470.00 to cover the above fees is enclosed.  
 4. ☐ Please charge my Deposit Account No. 14-1140 in the amount of \$\_\_\_\_\_ to cover the above fees. A duplicate copy of this form is enclosed.  
 5. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A duplicate copy of this form is enclosed.  
 6. ☒ The entire content of the foreign application(s), referred to in this application is/are hereby incorporated by reference in this application.

**NOTE:** Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

**SEND ALL CORRESPONDENCE TO:**

**WIXON & VANDERHYE P.C.**  
 100 North Glebe Road, 8<sup>th</sup> Floor  
 Arlington, Virginia 22201-4714  
 Telephone: (703) 816-4000

SIGNATURE   
**Leonard C. Mitchard**  
 NAME

29,009 June 25, 2001  
 REGISTRATION NUMBER Date

#4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of

FRASER et al

Atty. Ref.: 3911-8

Serial No. 09/869,136

Group:

Filed: June 25, 2001

Examiner:

For: SUPERANTIGENS

\* \* \* \* \*

November 29, 2001

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

**RESPONSE**

Responsive to the Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed August 1, 2001, please amend the above application as follows.

**IN THE SPECIFICATION**

Please substitute the following paragraph beginning at page 2, line 18 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Fig 1: Multiple alignment of superantigen protein sequences (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance).

Please substitute the following paragraph beginning at page 5, line 11 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Figure 1 (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance) shows the amino acid sequences of the above four superantigens together with those of previously identified superantigens SMEZ, SPE-C and SEA.

Please substitute the following paragraph beginning at page 5, line 26 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS (SEQ ID NO:9) sequence of SMEZ is converted to KTSIL (SEQ ID NO:2) in SMEZ-2 (Fig. 1). A second difference is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

Please substitute the following paragraph beginning at page 5, line 31 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Figure 2 (SEQ ID NOS:1-2) shows the nucleotide sequence encoding mature SMEZ-2 and the deduced amino acid sequence.

Please substitute the following paragraph beginning at page 6, line 1 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Likewise, Figures 3 to 5 (SEQ ID NOS:3-8) show the nucleotide sequence encoding mature SPE-G, SPE-H and SPE-J superantigens, respectively, together with their respective deduced amino acid sequences.

Please substitute the following paragraph beginning at page 6, line 6 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

The invention is of course not restricted to superantigens/polynucleotides having the specific sequences of Figures 1 to 5 (SEQ ID NOS:1-11). Instead, functionally equivalent variants are contemplated.

Please substitute the following paragraphs beginning at page 15, line 5 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Fifty nanograms of *S.pyogenes* M1 (ATCC 700294) or *S.pyogenes* 2035 genomic DNA was used as a template to amplify the smeZ DNA fragment and the smeZ-2 DNA fragment, respectively, by PCR using the primers

smeZ-forward (TGGGATCCTTAGAAGTAGATAATA) (SEQ ID NO:12) and smeZ-reverse (AAGAATTCTTAGGAGTCAATTTC) (SEQ ID NO:13) and Taq Polymerase (Promega). The primers contain a terminal tag with the restriction enzyme recognition sequences BamHI and EcoRI, respectively. The amplified DNA fragment, encoding the mature protein without the leader sequence (Kamezawa et al, 1997 Infect. Immun. 65 no.9:38281-33) was cloned into a T-tailed pBlueScript SKII vector (Stratagene).

Spe-g and spe-h were cloned in similar approach, using the primers spe-g-fw

(CTGGATCCGATGAAAATTTAAAAGATTTAA) (SEQ ID NO:14) and spe-g-rev (AAGAATTCGGGGGGAGAATAG), (SEQ ID NO:15) and primers spe-h-fw (TTGGATCCAATTCTTATAATACAACC) (SEQ ID NO:16) and spe-h-rev (AAAAGCTTTTAGCTGATTGACAC), (SEQ ID NO:17) respectively.

Please substitute the following paragraph beginning at page 19, line 27 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS (SEQ ID NO:9) sequence of SMEZ is converted to KTSIL (SEQ ID NO:2) in SMEZ-2 (Fig. 1). A second cluster is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

Please substitute the following paragraph beginning at page 20, line 15 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Multiple alignment of SAg protein sequences (Fig. 1) (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance) shows that similarities are clustered within structure determining regions, represented by  $\alpha 4$ ,  $\alpha 5$ ,  $\beta 4$  and  $\beta 5$  regions. This applies to all toxins of the superantigen family (data not shown) and explains why superantigens like SPE-C and SEA have very similar overall structures despite their rather low sequence identity of 24.4%.

Please substitute the following paragraph beginning at page 29, line 34 in the specification for corresponding paragraphs previously presented. A copy of the amended specification paragraphs showing current revisions is attached.

Purified genomic DNA from all *Str. Pyogenes* isolates was used for PCR with specific primers for the smeZ, spe-g and spe-h genes as described above and by Proft (1999). In addition, a primer pair specific to a DNA region encoding the 23S, rRNA, oligo 23rRNA forward (SEQ ID NO:18) (GCTATTTTCGGAGAGAACCAG) and oligo 23rRNA reverse (SEQ ID NO:19) (CTGAAACATCTAAGTAGCTG) was designed and used for PCR as a positive control.



**REMARKS**


The above amendments have been made in compliance with the sequence listing requirements. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached pages are captioned **"Version With Markings To Show Changes Made."**

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION**

The paragraph beginning at page 2, line 18:

Fig 1: Multiple alignment of superantigen protein sequences (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance).

The paragraph beginning at page 5, line 11:

Figure 1 (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance) shows the amino acid sequences of the above four superantigens together with those of previously identified superantigens SMEZ, SPE-C and SEA.

The paragraph beginning at page 5, line 26:

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS (SEQ ID NO:9) sequence of SMEZ is converted to KTSIL (SEQ ID NO:2) in SMEZ-2 (Fig. 1). A second difference is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

The following paragraph beginning at page 5, line 31:

Figure 2 (SEQ ID NOS:1-2) shows the nucleotide sequence encoding mature SMEZ-2 and the deduced amino acid sequence.

The paragraph beginning at page 6, line 1:

Likewise, Figures 3 to 5 (SEQ ID NOS:3-8) show the nucleotide sequence encoding mature SPE-G, SPE-H and SPE-J superantigens, respectively, together with their respective deduced amino acid sequences.

The paragraph beginning at page 6, line 6:

The invention is of course not restricted to superantigens/polynucleotides having the specific sequences of Figures 1 to 5 (SEQ ID NOS:1-11). Instead, functionally equivalent variants are contemplated.

The paragraphs beginning at page 15, line 5:

Fifty nanograms of *S.pyogenes* M1 (ATCC 700294) or *S.pyogenes* 2035 genomic DNA was used as a template to amplify the smeZ DNA fragment and the smeZ-2 DNA fragment, respectively, by PCR using the primers

smez-forward (TGGGATCCTTAGAAGTAGATAATA) (SEQ ID NO:12) and

smez-reverse (AAGAATTCTTAGGAGTCAATTTC) (SEQ ID NO:13) and Taq Polymerase (Promega). The primers contain a terminal tag with the restriction enzyme recognition sequences BamHI and EcoRI, respectively. The amplified DNA fragment, encoding the mature protein without the leader sequence

(Kamezawa et al, 1997 Infect. Immun. 65 no.9:38281-33) was cloned into a T-tailed pBlueScript SKII vector (Stratagene).

Spe-g and spe-h were cloned in similar approach, using the primers spe-g-fw

(CTGGATCCGATGAAAATTTAAAAGATTAA) (SEQ ID NO:14) and spe-g-rev (AAGAATTCGGGGGGGAGAATAG), (SEQ ID NO:15) and primers spe-h-fw (TTGGATCCAATTCTTATAATACAACC) (SEQ ID NO:16) and spe-h-rev (AAAAGCTTTTAGCTGATTGACAC), (SEQ ID NO:17) respectively.

The paragraph beginning at page 19, line 27:

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS (SEQ ID NO:9) sequence of SMEZ is converted to KTSIL (SEQ ID NO:2) in SMEZ-2 (Fig. 1). A second cluster is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

The paragraph beginning at page 20, line 15:

Multiple alignment of SAg protein sequences (Fig. 1) (SEQ ID NOS:9, 2, 8, 10, 4 and 6, respectively, in order of appearance) shows that similarities are clustered within structure determining regions, represented by  $\alpha 4$ ,  $\alpha 5$ ,  $\beta 4$  and  $\beta 5$

regions. This applies to all toxins of the superantigen family (data not shown) and explains why superantigens like SPE-C and SEA have very similar overall structures despite their rather low sequence identity of 24.4%.

The paragraph beginning at page 29, line 34:

Purified genomic DNA from all *Str. Pyogenes* isolates was used for PCR with specific primers for the smeZ, spe-g and spe-h genes as described above and by Proft (1999). In addition, a primer pair specific to a DNA region encoding the 23S, rRNA, oligo 23rRNA forward (SEQ ID NO:18) (GCTATTTTCGGAGAGAACCAG) and oligo 23rRNA reverse (SEQ ID NO:19) (CTGAAACATCTAAGTAGCTG) was designed and used for PCR as a positive control.

PTO/PCT Rec'd 29 NOV 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 3911-8

In re patent application of

FRASER, JOHN DAVID et al.

Serial No. 09/869,136

Filed: July 20, 2001

For: SUPERANTIGENS

STATEMENT TO SUPPORT FILING AND SUBMISSION IN  
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231  
**Box SEQUENCE**

Sir:

In connection with a Sequence Listing submitted concurrently herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same; and


3. all statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 09/869,136

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Nov. 27, 2001  
Date

  
James A. Coburn

**HARBOR CONSULTING**  
Intellectual Property Services  
1500A Lafayette Road  
Suite 262  
Portsmouth, N.H.  
800-318-3021

PCT/NZ99/00228 29 NOV 2001

1

SEQUENCE LISTING

<110> FRASER, JOHN DAVID  
PROFT, THOMAS

<120> SUPERANTIGENS

<130> 3911-8

<140> 09/869,136

<141> 2001-07-20

<150> PCT/NZ99/00228

<151> 1999-12-24

<150> NZ 333589

<151> 1998-12-24

<160> 19

<170> PatentIn Ver. 2.1

<210> 1

<211> 702

<212> DNA

<213> Streptococcus pyogenes

<220>

<221> CDS

<222> (1)..(699)

<400> 1

```

atg aaa aaa aca aaa ctt att ttt tct ttt act tca ata ttc att gca      48
Met Lys Lys Thr Lys Leu Ile Phe Ser Phe Thr Ser Ile Phe Ile Ala
   1               5               10               15

ata att tct cgt cct gtg ttt gga tta gaa gta gat aat aat tcc ctt      96
Ile Ile Ser Arg Pro Val Phe Gly Leu Glu Val Asp Asn Asn Ser Leu
           20               25               30

cta agg aat atc tat agt acg att gta tat gaa tat tca gat ata gta      144
Leu Arg Asn Ile Tyr Ser Thr Ile Val Tyr Glu Tyr Ser Asp Ile Val
           35               40               45

att gat ttt aaa acc agt cat aac tta gtg act aag aaa ctt gat gtt      192
Ile Asp Phe Lys Thr Ser His Asn Leu Val Thr Lys Lys Leu Asp Val
           50               55               60

aga gat gct aga gat ttc ttt att aac tcc gaa atg gac gaa tat gca      240
Arg Asp Ala Arg Asp Phe Phe Ile Asn Ser Glu Met Asp Glu Tyr Ala
           65               70               75               80

gcc aat gat ttt aaa act gga gat aaa ata gct gtg ttc tcc gtc cca      288
Ala Asn Asp Phe Lys Thr Gly Asp Lys Ile Ala Val Phe Ser Val Pro
           85               90               95

```



ttt gat tgg aac tat tta tca aaa gga aaa gtc aca gca tat acc tat 336  
 Phe Asp Trp Asn Tyr Leu Ser Lys Gly Lys Val Thr Ala Tyr Thr Tyr  
                   100                                  105                                  110

ggg gga ata aca ccc tac caa aaa act tca ata cct aaa aat atc cct 384  
 Gly Gly Ile Thr Pro Tyr Gln Lys Thr Ser Ile Pro Lys Asn Ile Pro  
                   115                                  120                                  125

gtt aat tta tgg att aat gga aag cag atc tct gtt cct tac aac gaa 432  
 Val Asn Leu Trp Ile Asn Gly Lys Gln Ile Ser Val Pro Tyr Asn Glu  
                   130                                  135                                  140

ata tca act aac aaa aca aca gtt aca gct caa gaa att gat cta aag 480  
 Ile Ser Thr Asn Lys Thr Thr Val Thr Ala Gln Glu Ile Asp Leu Lys  
                   145                                  150                                  155                                  160

gtt aga aaa ttt tta ata gca caa cat caa tta tat tct tct ggt tct 528  
 Val Arg Lys Phe Leu Ile Ala Gln His Gln Leu Tyr Ser Ser Gly Ser  
                   165                                  170                                  175

agc tac aaa agt ggt aga ctg gtt ttt cat aca aat gat aat tca gat 576  
 Ser Tyr Lys Ser Gly Arg Leu Val Phe His Thr Asn Asp Asn Ser Asp  
                   180                                  185                                  190

aaa tat tct ttc gat ctt ttc tat gta gga tat aga gat aaa gaa agt 624  
 Lys Tyr Ser Phe Asp Leu Phe Tyr Val Gly Tyr Arg Asp Lys Glu Ser  
                   195                                  200                                  205

atc ttt aaa gta tac aaa gac aat aaa tct ttc aat ata gat aaa att 672  
 Ile Phe Lys Val Tyr Lys Asp Asn Lys Ser Phe Asn Ile Asp Lys Ile  
                   210                                  215                                  220

ggg cat tta gat ata gaa att gac tcc taa 702  
 Gly His Leu Asp Ile Glu Ile Asp Ser  
                   225                                  230

<210> 2

<211> 233

<212> PRT

<213> Streptococcus pyogenes

<400> 2

Met Lys Lys Thr Lys Leu Ile Phe Ser Phe Thr Ser Ile Phe Ile Ala  
           1                                  5                                  10                                  15

Ile Ile Ser Arg Pro Val Phe Gly Leu Glu Val Asp Asn Asn Ser Leu  
                   20                                  25                                  30

Leu Arg Asn Ile Tyr Ser Thr Ile Val Tyr Glu Tyr Ser Asp Ile Val  
           35                                  40                                  45

Ile Asp Phe Lys Thr Ser His Asn Leu Val Thr Lys Lys Leu Asp Val  
           50                                  55                                  60

Arg Asp Ala Arg Asp Phe Phe Ile Asn Ser Glu Met Asp Glu Tyr Ala  
           65                                  70                                  75                                  80

Ala Asn Asp Phe Lys Thr Gly Asp Lys Ile Ala Val Phe Ser Val Pro  
85 90 95

Phe Asp Trp Asn Tyr Leu Ser Lys Gly Lys Val Thr Ala Tyr Thr Tyr  
100 105 110

Gly Gly Ile Thr Pro Tyr Gln Lys Thr Ser Ile Pro Lys Asn Ile Pro  
115 120 125

Val Asn Leu Trp Ile Asn Gly Lys Gln Ile Ser Val Pro Tyr Asn Glu  
130 135 140

Ile Ser Thr Asn Lys Thr Thr Val Thr Ala Gln Glu Ile Asp Leu Lys  
145 150 155 160

Val Arg Lys Phe Leu Ile Ala Gln His Gln Leu Tyr Ser Ser Gly Ser  
165 170 175

Ser Tyr Lys Ser Gly Arg Leu Val Phe His Thr Asn Asp Asn Ser Asp  
180 185 190

Lys Tyr Ser Phe Asp Leu Phe Tyr Val Gly Tyr Arg Asp Lys Glu Ser  
195 200 205

Ile Phe Lys Val Tyr Lys Asp Asn Lys Ser Phe Asn Ile Asp Lys Ile  
210 215 220

Gly His Leu Asp Ile Glu Ile Asp Ser  
225 230

<210> 3  
<211> 705  
<212> DNA  
<213> Streptococcus pyogenes

<220>  
<221> CDS  
<222> (1)..(702)

<400> 3  
atg aaa aca aac att ttg aca att atc ata tta tca tgt gtt ttt agc 48  
Met Lys Thr Asn Ile Leu Thr Ile Ile Ile Leu Ser Cys Val Phe Ser  
1 5 10 15

tat gga agt caa tta gct tat gca gat gaa aat tta aaa gat tta aaa 96  
Tyr Gly Ser Gln Leu Ala Tyr Ala Asp Glu Asn Leu Lys Asp Leu Lys  
20 25 30

aga agt tta aga ttt gcc tat aat att acc cca tgc gat tat gaa aat 144  
Arg Ser Leu Arg Phe Ala Tyr Asn Ile Thr Pro Cys Asp Tyr Glu Asn  
35 40 45

gta gaa att gca ttt gtt act aca aat agc ata cat att aat act aaa 192  
Val Glu Ile Ala Phe Val Thr Thr Asn Ser Ile His Ile Asn Thr Lys  
50 55 60

```

caa aaa aga tcg gaa tgt att ctt tat gtt gat tct att gta tct tta 240
Gln Lys Arg Ser Glu Cys Ile Leu Tyr Val Asp Ser Ile Val Ser Leu
65 70 75 80

ggc att act gat cag ttt ata aaa ggg gat aag gtc gat gtt ttt ggt 288
Gly Ile Thr Asp Gln Phe Ile Lys Gly Asp Lys Val Asp Val Phe Gly
85 90 95

ctc cct tat aat ttt tcc cca cct tat gta gat aat att tat ggt ggt 336
Leu Pro Tyr Asn Phe Ser Pro Pro Tyr Val Asp Asn Ile Tyr Gly Gly
100 105 110

att gta aaa cat tcg aat caa gga aat aaa tca tta cag ttt gta gga 384
Ile Val Lys His Ser Asn Gln Gly Asn Lys Ser Leu Gln Phe Val Gly
115 120 125

att tta aat caa gat ggg aaa gaa act tat ttg ccc tct gag gct gtt 432
Ile Leu Asn Gln Asp Gly Lys Glu Thr Tyr Leu Pro Ser Glu Ala Val
130 135 140

cgc ata aaa aag aaa cag ttt act tta cag gaa ttt gat ttt aaa ata 480
Arg Ile Lys Lys Lys Gln Phe Thr Leu Gln Glu Phe Asp Phe Lys Ile
145 150 155 160

aga aaa ttt cta atg gaa aaa tac aat atc tat gat tcg gaa tcg cgt 528
Arg Lys Phe Leu Met Glu Lys Tyr Asn Ile Tyr Asp Ser Glu Ser Arg
165 170 175

tat aca tcg ggg agc ctt ttc ctt gct act aaa gat agt aaa cat tat 576
Tyr Thr Ser Gly Ser Leu Phe Leu Ala Thr Lys Asp Ser Lys His Tyr
180 185 190

gaa gtt gat tta ttt aat aag gat gat aag ctt tta agt cga gac agt 624
Glu Val Asp Leu Phe Asn Lys Asp Asp Lys Leu Leu Ser Arg Asp Ser
195 200 205

ttc ttt aaa agg tat aaa gat aat aag att ttt aat agt gaa gaa att 672
Phe Phe Lys Arg Tyr Lys Asp Asn Lys Ile Phe Asn Ser Glu Glu Ile
210 215 220

agt cat ttt gat atc tac tta aaa acg cac tag 705
Ser His Phe Asp Ile Tyr Leu Lys Thr His
225 230

```

<210> 4

<211> 234

<212> PRT

<213> Streptococcus pyogenes

<400> 4

```

Met Lys Thr Asn Ile Leu Thr Ile Ile Ile Leu Ser Cys Val Phe Ser
1 5 10 15

```

```

Tyr Gly Ser Gln Leu Ala Tyr Ala Asp Glu Asn Leu Lys Asp Leu Lys
20 25 30

```

Arg Ser Leu Arg Phe Ala Tyr Asn Ile Thr Pro Cys Asp Tyr Glu Asn  
35 40 45

Val Glu Ile Ala Phe Val Thr Thr Asn Ser Ile His Ile Asn Thr Lys  
50 55 60

Gln Lys Arg Ser Glu Cys Ile Leu Tyr Val Asp Ser Ile Val Ser Leu  
65 70 75 80

Gly Ile Thr Asp Gln Phe Ile Lys Gly Asp Lys Val Asp Val Phe Gly  
85 90 95

Leu Pro Tyr Asn Phe Ser Pro Pro Tyr Val Asp Asn Ile Tyr Gly Gly  
100 105 110

Ile Val Lys His Ser Asn Gln Gly Asn Lys Ser Leu Gln Phe Val Gly  
115 120 125

Ile Leu Asn Gln Asp Gly Lys Glu Thr Tyr Leu Pro Ser Glu Ala Val  
130 135 140

Arg Ile Lys Lys Lys Gln Phe Thr Leu Gln Glu Phe Asp Phe Lys Ile  
145 150 155 160

Arg Lys Phe Leu Met Glu Lys Tyr Asn Ile Tyr Asp Ser Glu Ser Arg  
165 170 175

Tyr Thr Ser Gly Ser Leu Phe Leu Ala Thr Lys Asp Ser Lys His Tyr  
180 185 190

Glu Val Asp Leu Phe Asn Lys Asp Asp Lys Leu Leu Ser Arg Asp Ser  
195 200 205

Phe Phe Lys Arg Tyr Lys Asp Asn Lys Ile Phe Asn Ser Glu Glu Ile  
210 215 220

Ser His Phe Asp Ile Tyr Leu Lys Thr His  
225 230

<210> 5

<211> 711

<212> DNA

<213> Streptococcus pyogenes

<220>

<221> CDS

<222> (1)..(708)

<400> 5

atg aga tat aat tgt cgc tac tca cat att gat aag aaa atc tac agc 48  
Met Arg Tyr Asn Cys Arg Tyr Ser His Ile Asp Lys Lys Ile Tyr Ser  
1 5 10 15

atg att ata tgt ttg tca ttt ctt tta tat tcc aat gtt gtt caa gca 96  
Met Ile Ile Cys Leu Ser Phe Leu Leu Tyr Ser Asn Val Val Gln Ala  
20 25 30

aat tct tat aat aca acc aat aga cat aat cta gaa tcg ctt tat aag	144
Asn Ser Tyr Asn Thr Thr Asn Arg His Asn Leu Glu Ser Leu Tyr Lys	
35 40 45	
cat gat tct aac ttg att gaa gcc gat agt ata aaa aat tct cca gat	192
His Asp Ser Asn Leu Ile Glu Ala Asp Ser Ile Lys Asn Ser Pro Asp	
50 55 60	
att gta aca agc cat atg ttg aaa tat agt gtc aag gat aaa aat ttg	240
Ile Val Thr Ser His Met Leu Lys Tyr Ser Val Lys Asp Lys Asn Leu	
65 70 75 80	
tca gtt ttt ttt gag aaa gat tgg ata tca cag gaa ttc aaa gat aaa	288
Ser Val Phe Phe Glu Lys Asp Trp Ile Ser Gln Glu Phe Lys Asp Lys	
85 90 95	
gaa gta gat att tat gct cta tct gca caa gag gtt tgt gaa tgt cca	336
Glu Val Asp Ile Tyr Ala Leu Ser Ala Gln Glu Val Cys Glu Cys Pro	
100 105 110	
ggg aaa agg tat gaa gcg ttt ggt gga att aca tta act aat tca gaa	384
Gly Lys Arg Tyr Glu Ala Phe Gly Gly Ile Thr Leu Thr Asn Ser Glu	
115 120 125	
aaa aaa gaa att aaa gtt cct gta aac gtg tgg gat aaa agt aaa caa	432
Lys Lys Glu Ile Lys Val Pro Val Asn Val Trp Asp Lys Ser Lys Gln	
130 135 140	
cag ccg cct atg ttt att aca gtc aat aaa ccg aaa gta acc gct cag	480
Gln Pro Pro Met Phe Ile Thr Val Asn Lys Pro Lys Val Thr Ala Gln	
145 150 155 160	
gaa gtg gat ata aaa gtt aga aag tta ttg att aag aaa tac gat atc	528
Glu Val Asp Ile Lys Val Arg Lys Leu Leu Ile Lys Lys Tyr Asp Ile	
165 170 175	
tat aat aac cgg gaa caa aaa tac tct aaa gga act gtt acc tta gat	576
Tyr Asn Asn Arg Glu Gln Lys Tyr Ser Lys Gly Thr Val Thr Leu Asp	
180 185 190	
tta aat tca ggt aaa gat att gtt ttt gat ttg tat tat ttt ggc aat	624
Leu Asn Ser Gly Lys Asp Ile Val Phe Asp Leu Tyr Tyr Phe Gly Asn	
195 200 205	
gga gac ttt aat agc atg cta aaa ata tat tcc aat aac gag aga ata	672
Gly Asp Phe Asn Ser Met Leu Lys Ile Tyr Ser Asn Asn Glu Arg Ile	
210 215 220	
gac tca act caa ttt cat gta gat gtg tca atc agc taa	711
Asp Ser Thr Gln Phe His Val Asp Val Ser Ile Ser	
225 230 235	

&lt;210&gt; 6

&lt;211&gt; 236

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 6

Met Arg Tyr Asn Cys Arg Tyr Ser His Ile Asp Lys Lys Ile Tyr Ser  
 1 5 10 15

Met Ile Ile Cys Leu Ser Phe Leu Leu Tyr Ser Asn Val Val Gln Ala  
 20 25 30

Asn Ser Tyr Asn Thr Thr Asn Arg His Asn Leu Glu Ser Leu Tyr Lys  
 35 40 45

His Asp Ser Asn Leu Ile Glu Ala Asp Ser Ile Lys Asn Ser Pro Asp  
 50 55 60

Ile Val Thr Ser His Met Leu Lys Tyr Ser Val Lys Asp Lys Asn Leu  
 65 70 75 80

Ser Val Phe Phe Glu Lys Asp Trp Ile Ser Gln Glu Phe Lys Asp Lys  
 85 90 95

Glu Val Asp Ile Tyr Ala Leu Ser Ala Gln Glu Val Cys Glu Cys Pro  
 100 105 110

Gly Lys Arg Tyr Glu Ala Phe Gly Gly Ile Thr Leu Thr Asn Ser Glu  
 115 120 125

Lys Lys Glu Ile Lys Val Pro Val Asn Val Trp Asp Lys Ser Lys Gln  
 130 135 140

Gln Pro Pro Met Phe Ile Thr Val Asn Lys Pro Lys Val Thr Ala Gln  
 145 150 155 160

Glu Val Asp Ile Lys Val Arg Lys Leu Leu Ile Lys Lys Tyr Asp Ile  
 165 170 175

Tyr Asn Asn Arg Glu Gln Lys Tyr Ser Lys Gly Thr Val Thr Leu Asp  
 180 185 190

Leu Asn Ser Gly Lys Asp Ile Val Phe Asp Leu Tyr Tyr Phe Gly Asn  
 195 200 205

Gly Asp Phe Asn Ser Met Leu Lys Ile Tyr Ser Asn Asn Glu Arg Ile  
 210 215 220

Asp Ser Thr Gln Phe His Val Asp Val Ser Ile Ser  
 225 230 235

&lt;210&gt; 7

&lt;211&gt; 414

&lt;212&gt; DNA

&lt;213&gt; Streptococcus pyogenes

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(411)

&lt;400&gt; 7

ctt ccg tac ata ttt act cgt tat gat gtt tat tat ata tat ggt ggg 48  
 Leu Pro Tyr Ile Phe Thr Arg Tyr Asp Val Tyr Tyr Ile Tyr Gly Gly  
 1 5 10 15

gtt aca cca tca gta aac agt aat tcg gaa aat agt aaa att gta ggt 96  
 Val Thr Pro Ser Val Asn Ser Asn Ser Glu Asn Ser Lys Ile Val Gly  
 20 25 30

aat tta cta ata gat gga gtc cag caa aaa aca cta ata aat ccc ata 144  
 Asn Leu Leu Ile Asp Gly Val Gln Gln Lys Thr Leu Ile Asn Pro Ile  
 35 40 45

aaa ata gat aaa cct att ttt acg att caa gaa ttt gac ttc aaa atc 192  
 Lys Ile Asp Lys Pro Ile Phe Thr Ile Gln Glu Phe Asp Phe Lys Ile  
 50 55 60

aga caa tat ctt atg caa aca tac aaa att tat gat cct aat tct cca 240  
 Arg Gln Tyr Leu Met Gln Thr Tyr Lys Ile Tyr Asp Pro Asn Ser Pro  
 65 70 75 80

tac ata aaa ggg caa tta gaa att gcg atc aat ggc aat aaa cat gaa 288  
 Tyr Ile Lys Gly Gln Leu Glu Ile Ala Ile Asn Gly Asn Lys His Glu  
 85 90 95

agt ttt aac tta tat gat gca acc tca tct agt aca agg agt gat att 336  
 Ser Phe Asn Leu Tyr Asp Ala Thr Ser Ser Ser Thr Arg Ser Asp Ile  
 100 105 110

ttt aaa aaa tat aaa gac aat aag act ata aat atg aaa gat ttc agc 384  
 Phe Lys Lys Tyr Lys Asp Asn Lys Thr Ile Asn Met Lys Asp Phe Ser  
 115 120 125

cat ttt gat att tac ctt tgg act aaa taa 414  
 His Phe Asp Ile Tyr Leu Trp Thr Lys  
 130 135

&lt;210&gt; 8

&lt;211&gt; 137

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 8

Leu Pro Tyr Ile Phe Thr Arg Tyr Asp Val Tyr Tyr Ile Tyr Gly Gly  
 1 5 10 15

Val Thr Pro Ser Val Asn Ser Asn Ser Glu Asn Ser Lys Ile Val Gly  
 20 25 30

Asn Leu Leu Ile Asp Gly Val Gln Gln Lys Thr Leu Ile Asn Pro Ile  
 35 40 45

Lys Ile Asp Lys Pro Ile Phe Thr Ile Gln Glu Phe Asp Phe Lys Ile  
 50 55 60

Arg Gln Tyr Leu Met Gln Thr Tyr Lys Ile Tyr Asp Pro Asn Ser Pro  
 65 70 75 80

```
<210> 9
<211> 204
<212> PRT
<213> Streptococcus pyogenes
```

<400> 9																
Leu	Glu	Val	Asp	Asn	Asn	Ser	Leu	Leu	Arg	Asn	Ile	Tyr	Ser	Thr	Ile	
1				5					10					15		
Val	Tyr	Glu	Tyr	Ser	Asp	Thr	Val	Ile	Asp	Phe	Lys	Thr	Ser	His	Asn	
			20					25					30			
Leu	Val	Thr	Lys	Lys	Leu	Asp	Val	Arg	Asp	Ala	Arg	Asp	Phe	Phe	Ile	
		35					40					45				
Asn	Ser	Glu	Met	Asp	Glu	Tyr	Ala	Ala	Asn	Asp	Phe	Lys	Asp	Gly	Asp	
	50					55					60					
Lys	Ile	Ala	Met	Phe	Ser	Val	Pro	Phe	Asp	Trp	Asn	Tyr	Leu	Ser	Glu	
65					70					75					80	
Gly	Lys	Val	Ile	Ala	Tyr	Thr	Tyr	Gly	Met	Thr	Pro	Tyr	Gln	Glu	Glu	
				85					90					95		
Pro	Met	Ser	Lys	Asn	Ile	Pro	Val	Leu	Trp	Ile	Asn	Arg	Arg	Gln	Ile	
			100					105					110			
Pro	Val	Pro	Tyr	Asn	Gln	Ile	Ser	Thr	Asn	Lys	Thr	Thr	Val	Thr	Ala	
		115					120					125				
Gln	Glu	Ile	Asp	Leu	Lys	Val	Lys	Phe	Leu	Ile	Ser	Gln	His	Gln	Leu	
	130					135					140					
Ser	Ser	Gly	Ser	Ser	Tyr	Lys	Ser	Gly	Lys	Leu	Val	Phe	His	Thr	Asn	
145					150					155					160	
Asp	Asn	Ser	Asp	Lys	Tyr	Ser	Leu	Asp	Leu	Phe	Tyr	Val	Gly	Tyr	Arg	
				165					170					175		
Asp	Lys	Glu	Ser	Ile	Phe	Lys	Val	Tyr	Lys	Asp	Lys	Ser	Phe	Asn	Ile	
			180					185					190			



Asp Lys Ile Gly His Leu Asp Ile Glu Ile Asp Ser  
195 200

<210> 10

<211> 203

<212> PRT

<213> Streptococcus pyogenes

<400> 10

Asp Ser Lys Lys Asp Ile Ser Asn Val Lys Ser Asp Leu Leu Tyr Ala  
1 5 10 15

Tyr Thr Ile Thr Pro Tyr Asp Tyr Lys Asp Cys Arg Val Asn Phe Ser  
20 25 30

Thr Thr His Thr Leu Asn Ile Asp Thr Gln Lys Tyr Arg Gly Lys Asp  
35 40 45

Tyr Tyr Ile Ser Ser Glu Met Ser Tyr Glu Ala Ser Gln Lys Phe Lys  
50 55 60

Arg Asp Asp His Val Asp Val Phe Gly Leu Phe Tyr Ile Leu Asn Ser  
65 70 75 80

His Thr Gly Glu Tyr Ile Tyr Gly Ile Thr Pro Ala Gln Asn Asn Lys  
85 90 95

Val Asn His Lys Leu Leu Gly Leu Phe Ile Ser Gly Glu Ser Gln Gln  
100 105 110

Asn Leu Asn Asn Lys Ile Ile Leu Glu Lys Asp Ile Val Thr Phe Gln  
115 120 125

Glu Ile Asp Phe Lys Ile Lys Tyr Leu Met Asp Asn Tyr Lys Ile Asp  
130 135 140

Ala Thr Ser Pro Tyr Val Ser Gly Arg Ile Glu Ile Gly Thr Lys Asp  
145 150 155 160

Gly Lys His Glu Gln Ile Asp Leu Phe Asp Ser Pro Asn Glu Gly Thr  
165 170 175

Arg Ser Asp Ile Phe Ala Lys Tyr Lys Asp Arg Ile Ile Asn Met Lys  
180 185 190

Asn Phe Ser His Phe Asp Ile Tyr Leu Glu Lys  
195 200

<210> 11

<211> 227

<212> PRT

<213> Staphylococcus aureus

<400> 11

Ser Glu Lys Ser Glu Glu Ile Asn Glu Lys Asp Leu Arg Lys Lys Ser  
1 5 10 15

Glu Leu Gln Gly Ala Ala Leu Gly Asn Lys Gln Ile Tyr Tyr Tyr Asn  
                   20                  25                  30  
 Glu Lys Ala Lys Thr Glu Asn Lys Glu Ser His Asp Gln Phe Leu Gln  
                   35                  40                  45  
 His Thr Ile Leu Phe Lys Gly Phe Phe Thr Asn His Ser Trp Tyr Asn  
                   50                  55                  60  
 Asp Leu Leu Val Asp Phe Asp Ser Lys Asp Ile Val Asp Lys Tyr Lys  
                   65                  70                  75                  80  
 Gly Lys Lys Val Asp Leu Tyr Gly Ala Tyr Tyr Gly Tyr Gln Cys Ala  
                   85                  90                  95  
 Gly Gly Thr Pro Asn Lys Thr Ala Cys Met Tyr Gly Val Thr Leu His  
                   100                  105                  110  
 Asp Asn Asn Arg Leu Thr Glu Glu Lys Lys Val Pro Ile Asn Leu Trp  
                   115                  120                  125  
 Leu Asp Lys Gln Asn Thr Val Pro Leu Glu Thr Val Lys Thr Asn Lys  
                   130                  135                  140  
 Lys Asn Val Thr Val Gln Glu Leu Asp Leu Gln Ala Arg Tyr Leu Gln  
                   145                  150                  155                  160  
 Glu Lys Tyr Asn Leu Asn Ser Asp Val Phe Asp Gly Lys Val Gln Arg  
                   165                  170                  175  
 Gly Leu Ile Val Phe His Thr Ser Thr Glu Pro Ser Val Asn Tyr Asp  
                   180                  185                  190  
 Leu Phe Gly Ala Gln Gly Gln Asn Ser Asn Thr Leu Leu Arg Ile Tyr  
                   195                  200                  205  
 Arg Asp Lys Thr Ile Asn Ser Glu Asn Met His Ile Asp Ile Tyr Leu  
                   210                  215                  220  
 Tyr Thr Ser  
 225

&lt;210&gt; 12

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Primer

&lt;400&gt; 12

tgggatcctt agaagtagat aata

24

&lt;210&gt; 13

&lt;211&gt; 23

<212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 13  
 aagaattctt aggagtcaat ttc 23

<210> 14  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 14  
 ctggatccga tgaaaattta aaagatttaa 30

<210> 15  
 <211> 21  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 15  
 aagaattcgg ggggagaata g 21

<210> 16  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 16  
 ttgatccaa ttcttataat acaacc 26

<210> 17  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Primer

<400> 17  
 aaaagctttt agctgattga cac 23

<210> 18  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 18  
gctatttcgg agagaaccag

20

<210> 19  
<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>  
<223> Description of Artificial Sequence: Primer

<400> 19  
ctgaaacatc taagtagctg

20

24. (Amended) A kit which includes an antibody as claimed in claim 20.

29. (Amended) A kit which includes a nucleic acid molecule as claimed  
in claim 25.

**REMARKS**


The above amendments have been made to place the application in a more traditional format.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captioned "**Version With Markings To Show Changes Made.**"

Respectfully submitted,

**NIXON & VANDERHYE P.C.**

By: \_\_\_\_\_

  
Leonard C. Mitchard  
Reg. No. 29,009

LCM:lks  
1100 North Glebe Road, 8th Floor  
Arlington, VA 22201-4714  
Telephone: (703) 816-4000  
Facsimile: (703) 816-4100

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE CLAIMS**

15. (Amended) A method of subtyping Streptococci which includes the step of detecting the presence or absence of a polynucleotide as claimed in [any one of claims 6, 8, 10 or 12] claim 6.

24. (Amended) A kit which includes an antibody as claimed in [any one of claims 20 to 23] claim 20.

29. (Amended) A kit which includes a nucleic acid molecule as claimed in [any one of claims 25 to 28] claim 25.

**SUPERANTIGENS****TECHNICAL FIELD**

- 5 This invention relates to superantigens, and to their use, including in diagnosis and/or treatment of disease.

**BACKGROUND ART**

- 10 Bacterial superantigens are the most potent T cell mitogens known. They stimulate large numbers of T cells by directly binding to the side of the MHC class II and T cell Receptor (TcR) molecules. Because they override the normally exquisite MHC restriction phenomenon of T cell antigen recognition, they are prime candidates for either causing the onset of autoimmune diseases or exacerbating an existing  
15 autoimmune disorder.

The applicants have identified genes coding for four novel superantigens from *S. pyogenes*. It is broadly to these superantigens and polynucleotides encoding them that the present invention is directed.

20

**SUMMARY OF THE INVENTION**

In one aspect the invention provides a superantigen selected from any one of SMEZ-2, SPE-G, SPE-H and SPE-J, or a functionally equivalent variant thereof.

25

In a further aspect the invention provides a polynucleotide molecule comprising a sequence encoding a superantigen chosen from SMEZ-2, SPE-G, SPE-H, SPE-J, or a functionally equivalent variant thereof.

- 30 In another aspect of the invention there is provided a method of subtyping *Streptococci* on the basis of superantigen genotype comprising detection of the presence of any or all of the above four superantigens or the corresponding polynucleotides.



In a further aspect the invention provides a construct comprising any of the above superantigens (or superantigen variants) bound to a cell-targeting molecule, which is preferably a tumour-specific antibody.

- 5 In yet a further aspect, the invention provides a pharmaceutical composition for therapy or prophylaxis comprising a superantigen or superantigen variant as described above linked to cell targeting molecule.

Other aspects of the invention will be apparent from the description provided below,  
10 and from the appended claims.

#### DESCRIPTION OF DRAWINGS

While the invention is broadly defined above, it further includes embodiments of  
15 which the following description provides examples. It will also be better understood with reference to the following drawings:

Fig 1: Multiple alignment of superantigen protein sequences.

- 20 The protein sequence of mature toxins were aligned using the PileUp programme on the GCG package. Regions of high sequence identity are in black boxes. The boxes below the sequences indicate the structural elements of SPE-C, as determined from the crystal structure (Roussel et al 1997 Nat. Struct. Biol. 4 no8:635-43). Regions with highest homology correspond to the  $\beta 4$ ,  $\beta 5$ ,  $\alpha 4$  and  $\alpha 5$  regions in SPE-C. The  
25 clear box near the C-terminus represents a primary zinc binding motif, a common feature of all toxins shown. The arrows on top of the sequence alignment show the regions of sequence diversity between SMEZ and SMEZ-2.

Figure 2: The nucleotide sequence of the portion of the sme-2 gene (SEQ ID NO. 1)  
30 coding the mature SMEZ-2 superantigen (SEQ ID NO. 2).

Figure 3: The nucleotide sequence of the portion of the spe-g gene (SEQ ID NO. 3) coding the mature SPE-G superantigen (SEQ ID NO. 4).

Figure 4: The nucleotide sequence of the portion of the spe-h gene (SEQ ID NO. 5) coding the mature SPE-H superantigen (SEQ ID NO. 6).

Figure 5: The nucleotide sequence of the portion of the spe-j gene (SEQ ID NO. 7) coding part of the mature SPE-J superantigen (SEQ ID NO. 8).

Figure 6: Gel electrophoresis of the purified recombinant toxins.

A. Two micrograms of purified recombinant toxin were run on a 12.5% SDS-polyacrylamide gel to show the purity of the preparations; B. Two micrograms of purified recombinant toxin were run on an isoelectric focusing gel (5.5% PAA, pH 5-8). The isoelectric point (IEP) of rSMEZ-2, rSPE-G and rSPE-H is similar and was estimated at pH 7-8. The IEP of rSMEZ was estimated at pH 6-6.5.

Figure 7: Stimulation of human T cells with recombinant toxins.

PBLs were isolated from human blood samples and incubated with varying concentrations of recombinant toxin. After 3d, 0.1  $\mu$ Ci [ $^3$ H]-thymidine was added and cells were incubated for another 24h, before harvested and counted on a gamma counter. O, unstimulated;  $\blacktriangle$ , rSMEZ;  $\tilde{Z}$ , rSMEZ-2;  $\blacklozenge$ , rSPE-G;  $\blacksquare$ , rSPE-H.

Figure 8: Jurkat cell assay

Jurkat cells (bearing a V $\beta$ 8 TcR) and LG-2 cells were mixed with varying concentrations of recombinant toxin and incubated for 24h, before Sei cells were added. After 1d, 0.1  $\mu$ Ci [ $^3$ H]-thymidine was added and cells were counted after another 24h. The V $\beta$ 8 targeting SEE was used as a positive control. The negative control was SEA. Both SMEZ and SMEZ-2 were potent stimulators of Jurkat cells, indicating their ability to specifically target V $\beta$ 8 bearing T cells. O, unstimulated;  $\blacktriangle$ , rSEA;  $\tilde{Z}$ , rSEE;  $\blacklozenge$ , rSMEZ;  $\blacksquare$ , rSMEZ-2.

Figure 9: Zinc dependent binding of SMEZ-2 to LG-2 cells

LG-2 cells were incubated in duplicates with 1 ng of  $^{125}\text{I}$  labelled rSMEZ-2 and increasing amounts of unlabeled toxin at 37°C for 1h, and then the cells were washed and counted.

- 5 O, incubation in media; ▲, incubation in media plus 1mM EDTA; Ž, incubation in media plus 1 mM EDTA, 2 mM  $\text{ZnCl}_2$ .

Figure 10: Scatchard analysis of SMEZ-2 binding to LG-2 cells

- 10 One nanogram  $^{125}\text{I}$ -labeled rSMEZ-2 was incubated in duplicates with LG-2 cells and a 2-fold dilution series of cold toxin (10  $\mu\text{g}$  to 10 pg). After 1h, cells were washed and counted. Scatchard plots were performed as described by Cunningham et al 1989 Science 243:1330-1336.

- 15 Figure 11: Summary of competitive binding experiments.

Efficiency of each labelled toxin to compete with a 10,000-fold molar excess of any other unlabeled toxin for binding to LG-2 cells. □, no competition; □, 25% competition; □, 50% competition; □, 75% competition; ■, 100% competition.

- 20 The results within the boxes are at the bottom right have previously been published (Li et al. 1997).

Figure 12: Competition binding study with SMEZ-2.

- 25 LG-2 cells were incubated in duplicates with 1 ng of  $^{125}\text{I}$ -labeled rSMEZ-2 and increasing amounts of unlabeled rSMEZ-2, rSEA, rSEB, rTSST or rSPE-C. After 1h cells were washed and counted.

O, rSMEZ-2; ▲, rSEA; Ž, rSEB; ■ rTSST; ◆, rSPE-C.

- 30 Figure 13: Southern blot analysis of genomic DNA with radiolabeled smeZ. HINDIII digested genomic DNA from various *Streptococcus* isolates was hybridized with a radiolabeled smeZ probe. Band A is a 1953 bp HindIII DNA fragment that carries the smeZ gene. Bands B and C are DNA fragments of about 4 kbp and 4.2 kbp, respectively, which both carry a smeZ like region. 1, *S. pyogenes* reference strain (ATCC 700294, M1 type); 2, isolate 9639 (MNT); 3, isolate 11789 (MNT); 4, isolate
- 35

11152 (PT2612 type); 5, isolate RC4063 (group C streptococcus); 6, isolate 11070 (emm65 type); 7, DNA marker lane; 8, isolate 4202 (NZ5118/M92 type); 9, isolate 94/229 (M49 type); 10, isolate 11610 (emm57 type); 11, isolate 95/127 (NZ1437/M89 type); 12, isolate 94/330 (M4 type).

5

## DESCRIPTION OF THE INVENTION

The focus of the invention is the identification of four superantigens (SPE-G, SPE-H, SPE-J and SMEZ-2) and the corresponding polynucleotides which encode them.

10

Figure 1 shows the amino acid sequences of the above four superantigens together with those of previously identified superantigens SMEZ, SPE-C and SEA.

15

Of the four superantigens SPE-G, SPE-H, SPE-J and SMEZ-2, the latter is perhaps of greatest interest.

20

The smeZ-2 gene which encodes SMEZ-2 was identified in an experiment designed to produce recombinant SMEZ protein from *S. pyogenes* 2035 genomic DNA. A full length smeZ gene was isolated from the strain but the DNA sequence of the smeZ gene of strain 2035 showed nucleotide changes in 36 positions (or 5%) compared to smeZ from strain M1 (Fig. 1). The deduced protein sequences differed in 17 amino acid residues (or 8.1%). This difference establishes this as a new gene, smeZ-2, and the encoded protein as a new superantigen, SMEZ-2.

25

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS sequence of SMEZ is converted to KTSIL in SMEZ-2 (Fig. 1). A second difference is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

30

Figure 2 shows the nucleotide sequence encoding mature SMEZ-2 and the deduced amino acid sequence.

Likewise, Figures 3 to 5 show the nucleotide sequence encoding mature SPE-G, SPE-H and SPE-J superantigens, respectively, together with their respective deduced amino acid sequences.

- 5 The invention is of course not restricted to superantigens/polynucleotides having the specific sequences of Figures 1 to 5. Instead, functionally equivalent variants are contemplated.

The phrase "functionally equivalent variants" recognises that it is possible to vary  
10 the amino acid/nucleotide sequence of a peptide while retaining substantially equivalent functionality. For example, a peptide can be considered a functional equivalent of another peptide for a specific function if the equivalent peptide is immunologically cross-reactive with and has at least substantially the same function as the original peptide. The equivalent can be, for example, a fragment of  
15 the peptide, a fusion of the peptide with another peptide or carrier, or a fusion of a fragment which additional amino acids. For example, it is possible to substitute amino acids in a sequence with equivalent amino acids using conventional techniques. Groups of amino acids normally held to be equivalent are:

- 20 (a) Ala, Ser, Thr, Pro, Gly;  
(b) Asn, Asp, Glu, Gln;  
(c) His, Arg, Lys;  
(d) Met, Leu, Ile, Val; and  
(e) Phe, Tyr, Trp.

25

Equally, nucleotide sequences encoding a particular product can vary significantly simply due to the degeneracy of the nucleic acid code.

Variants can have a greater or lesser degree of homology as between the variant  
30 amino acid/nucleotide sequence and the original.

Polynucleotide or polypeptide sequences may be aligned, and percentage of identical nucleotides in a specified region may be determined against another sequence, using computer algorithms that are publicly available. Two exemplary algorithms  
35 for aligning and identifying the similarity of polynucleotide sequences are the

- BLASTN and FASTA algorithms. The similarity of polypeptide sequences may be examined using the BLASTP algorithm. Both the BLASTN and BLASTP software are available on the NCBI anonymous FTP server (<ftp://ncbi.nlm.nih.gov>) under /blast/executables/. The BLASTN algorithm version 2.0.4 [Feb-24-1998], set to the
- 5 default parameters described in the documentation of variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN and BLASTP, is described at NCBI's website at URL <http://www.ncbi.nlm.nih.gov/BLAST/newblast.html> and in the publication of Altschul, Stephen F., *et al.* (1997), "Gapped BLAST and PSI-BLAST: a new
- 10 generation of protein database search programs", *Nucleic Acids Res.* 25:3389-34023. The computer algorithm FASTA is available on the Internet at the ftp site <ftp://ftp.virginia.edu/pub/fasta/>. Version 2.0u4, February 1996, set to the default parameters described in the documentation and distributed with the algorithm, is
- 15 also preferred for use in the determination of variants according to the present invention. The use of the FASTA algorithm is described in W. R. Pearson and D. J. Lipman, "Improved Tools for Biological Sequence Analysis", *Proc. Natl. Acad. Sci. USA* 85:2444-2448 (1988) and W. R. Pearson, "Rapid and Sensitive Sequence Comparison with FASTP and FASTA", *Methods in Enzymology* 183:63-98 (1990).
- 20 The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to E values (as discussed below) and percentage identity: Unix running command: `blastall -p blastn -d embldb -e 10 -G 1 -E 1 -r 2 -v 50 -b 50 -i queryseq -o results`; and parameter default values:
- 25 `-p Program Name [String]`  
`-d Database [String]`  
`-e Expectation value (E) [Real]`  
`-G Cost to open a gap (zero invokes default behaviour) [Integer]`  
`-E Cost to extend a cap (zero invokes default behaviour) [Integer]`  
`-r Reward for a nucleotide match (blastn only) [Integer]`  
30 `-v Number of one-line descriptions (V) [Integer]`  
`-b Number of alignments to show (B) [Integer]`  
`-i Query File [File In]`  
`-o BLAST report Output File [File Out] Optional`
- For BLASTP the following running parameters are preferred: `blastall -p blastp -d`
- 35 `swissprotdb -e 10 -G 1 -E 1 -v 50 -b 50 -i queryseq -o results`

- p Program Name [String]
- d Database [String]
- e Expectation value (E) [Real]
- G Cost to open a gap (zero invokes default behaviour) [Integer]
- 5 -E Cost to extend a gap (zero invokes default behaviour) [Integer]
- v Number of one-line descriptions (v) [Integer]
- b Number of alignments to show (b) [Integer]
- i Query File [File In]
- o BLAST report Output File [File Out] Optional

10

The "hits" to one or more database sequences by a queried sequence produced by BLASTN, BLASTP, FASTA, or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.

15

20

The BLASTN and FASTA algorithms also produce "Expect" or E values for alignments. The E value indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database, such as the preferred EMBL database, indicates true similarity. For example, an E value of 0.1 assigned to a hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by chance. By this criterion, the aligned and matched portions of the sequences then have a 90% probability of being the same. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN or FASTA algorithm.

25

30

According to one embodiment, "variant" polynucleotides, with reference to each of the polynucleotides of the present invention, preferably comprise sequences having the same number or fewer nucleic acids than each of the polynucleotides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide of the present invention. That is, a variant polynucleotide is any sequence that has at least a 99% probability of being the same as the

35

polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN or FASTA algorithms set at the parameters discussed above.

Variant polynucleotide sequences will generally hybridize to the recited  
5 polynucleotide sequence under stringent conditions. As used herein, "stringent conditions" refers to prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.

10

The superantigens of the invention together with their fragments and other variants may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated by techniques well known to those of ordinary skill in the  
15 art. For example, such peptides may be synthesised using any of the commercially available solid-phase techniques such as the Merryfield solid phase synthesis method, where amino acids are sequentially added to a growing amino acid chain (see Merryfield, J. Am. Chem. Soc 85: 2146-2149 (1963)). Equipment for automative synthesis of peptides is commercially available from suppliers such as Perkin  
20 Elmer/Applied Biosystems, Inc. and may be operated according to the manufacturers instructions.

Each superantigen, or a fragment or variant thereof, may also be produced recombinantly by inserting a polynucleotide (usually DNA) sequence that encodes  
25 the superantigen into an expression vector and expressing the superantigen in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a DNA molecule which encodes the recombinant protein. Suitable host  
30 cells includes procaryotes, yeasts and higher eukaryotic cells. Preferably, the host cells employed are *E. coli*, yeasts or a mammalian cell line such as COS or CHO, or an insect cell line, such as SF9, using a baculovirus expression vector. The DNA sequence expressed in this matter may encode the naturally occurring superantigen, fragments of the naturally occurring protein or variants thereof.

35



- DNA sequences encoding the superantigen or fragments may be obtained, for example, by screening an appropriate *S. pyogenes* cDNA or genomic DNA library for DNA sequences that hybridise to degenerate oligonucleotides derived from partial amino acid sequences of the superantigen. Suitable degenerate oligonucleotides
- 5 may be designed and synthesised by standard techniques and the screen may be performed as described, for example, in Maniatis *et al.* Molecular Cloning - A Laboratory Manual, Cold Spring Harbour Laboratories, Cold Spring Harbour, NY (1989).
- 10 Identification of these superantigens and of their properties gives rise to a number of useful applications. A first such application is in the genotyping of organisms by reference to their superantigen profile.

An illustration of this is subtyping of strains of *S. pyogenes*.

- 15 One feature which has been observed is that all clones of *S. pyogenes* so far found to be positive for SMEZ express either SMEZ-1 or SMEZ-2 but not both. Thus they are mutually exclusive, which enables a rapid diagnostic test which tells whether an isolate or a patient sample is either SMEZ-1 +ve or SMEZ-2 +ve. This will assist in
- 20 the typing of the isolate.

- This general diagnostic approach is most simply achieved by providing a set or primers which amplify either all or a subset of superantigen genes and that generate gene specific fragments. This can be modified to provide a simple
- 25 qualitative ELISA-strip type kit that detects biotin labelled PCR fragments amplified by the specific primers and hybridised to immobilised sequence specific probes. This has usefulness for screening patient tissue samples for the presence of superantigen producing streptococcal strains.

- 30 Such approaches are well known and well understood by those persons skilled in the art.

- Another approach is to provide monoclonal antibodies to detect each of the streptococcal superantigens. An ELISA kit containing such antibodies would allow
- 35 the screening of large numbers of streptococcal isolates. A kit such as this would be

useful for agencies testing for patterns in streptococcal disease or food poisoning outbreaks.

Another potential diagnostic application of the superantigens of the invention is in the diagnosis of disease, such as Kawasaki Syndrome (KS).

KS is an acute multi-system vasculitis of unknown aetiology. It occurs world-wide but is most prevalent in Japan or in Japanese ancestry. It primarily affects infants and the young up to the age of 16. It is an acute disease that without treatment, can be fatal. Primary clinical manifestations include

- Prolonged fever
- Bilateral non-exudative conjunctivitis
- Induration and erythema of the extremities
- Inflammation of the lips and oropharynx
- Polymorphous skin rash
- Cervical lymphadenopathy
- In 15-25% of cases, coronary arterial lesions develop.

These indications are used as a primary diagnosis of KS.

In Japan and the US, KS has become one of the most common causes of acquired heart disease in children. Treatment involves the immediate intravenous administration of gamma globulin (IVGG) during the acute phase of the disease and this significantly reduces the level of coronary lesions.

There are two clear phases to the disease, an acute phase and a convalescent phase. The acute phase is marked by strong immune activation. Several reports have suggested that superantigens are involved and many attempts have been made to link the disease to infection with superantigen producing strains of *Streptococcus pyogenes*. Features of the acute phase of KS are the expansion of V $\beta$  2 and to a lesser extent V $\beta$ 8 bearing T cells and an increase of DR expression T cells (a hallmark of T cell activation).

Because SMEZ-2 stimulates both V $\beta$ 2 and V $\beta$ 8 bearing T cells, testing for SMEZ-2 production is potentially very useful in the diagnosis of KS.

Antibodies to the superantigens for use in applications such as are described above are also provided by this invention. Such antibodies can be polyclonal but will preferably be monoclonal antibodies.

5

Monoclonal antibodies with affinities of  $10^{-8}$  M<sup>-1</sup> or preferably  $10^{-9}$  to  $10^{-10}$  M<sup>-1</sup> or stronger will typically be made by standard procedures as described, eg. in Harlow & Lane (1988) or Goding (1986). Briefly, appropriate animals will be selected and the desired immunization protocol followed. After the appropriate period of time, the spleens of such animals are excised and individual spleen cells fused, typically, to immortalised myeloma cells under appropriate selection conditions. Thereafter, the cells are clonally separated and the supernatants of each clone tested for their production of an appropriate antibody specific for the desired region of the antigen.

10

Other suitable techniques for preparing antibodies well known in the art involve *in vitro* exposure of lymphocytes to the antigenic polypeptides, or alternatively, to selection of libraries of antibodies in phage or similar vectors.

15

Also, recombinant immunoglobulins may be produced using procedures known in the art (see, for example, US Patent 4,816,567 and Hodgson J. (1991)).

20

The antibodies may be used with or without modification. Frequently, antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in the literature. Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents, magnetic particles and the like. Patents teaching the use of such labels include US Patents 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437; 4,275,149; and 4,366,241.

25

30

The immunological assay in which the antibodies are employed can involve any convenient format known in the art.

The nucleotide sequence information provided herein may be used to design probes and primers for probing or amplification of parts of the sme-2, spe-g, spe-h and

35

spe-j genes. An oligonucleotide for use in probing or PCR may be about 30 or fewer nucleotides in length. Generally, specific primers are upwards of 14 nucleotides in length. For optimum specificity and cost effectiveness, primers of 16-24 nucleotides in length are preferred. Those skilled in the art are well versed in the design of primers for use in processes such as PCR.

If required, probing can be done with entire polynucleotide sequences provided herein as SEQ ID NOS 1, 3, 5 and 7, optionally carrying revealing labels or reporter molecules.

Such probes and primers also form aspects of the present invention.

Probing may employ the standard Southern blotting technique. For instance, DNA may be extracted from cells and digested with different restriction enzymes. Restriction fragments may then be separated by electrophoresis on an agarose gel, before denaturation and transfer to a nitrocellulose filter. Labelled probes may be hybridised to the DNA fragments on the filter and binding determined. DNA for probing may be prepared from RNA preparations from cells. Probing may optionally be done by means of so-called "nucleic acid chips" (see Marshall and Hodgson (1998) *Nature Biotechnology* 16:27-31).

In addition to diagnostic applications, another application of the superantigens is reliant upon their ability to bind to other cells.

One of the most important features of superantigens is that they bind a large number of T cell receptor molecules by binding to the V $\beta$  domain. They are the most potent of all T cell mitogens and are therefore useful to recruit and activate T cells in a relatively non-specific fashion.

This ability enables the formation of constructs in which the superantigen (or at least the T-cell binding portion of it) is coupled to a cell-targeting molecule, particularly an antibody, more usually a monoclonal antibody.

When a monoclonal antibody that targets a specific cell surface antigen (such as a tumor specific antigen) is coupled to a superantigen in such a construct, this generates a reagent that on the one hand will bind specifically to the tumor cell, and

on the other hand recruit and selectively active T cells for the purpose of killing the targeted cell.

5 Bi-specific constructs of this type have important applications in therapy (particularly cancer therapy) and again may be prepared by means known to those skilled in art. For example SMEZ-2 may be coupled to a tumor specific monoclonal antibody. The constructs may be incorporated into conventional carriers for pharmaceutically-active proteins.

10 Various aspects of the invention will now be described with reference to the following experimental section, which is included for illustrative purposes.

#### **EXAMPLE**

#### **15 SECTION A: SUPERANTIGEN IDENTIFICATION AND CHARACTERISATION**

##### ***Materials and Methods***

##### ***Identification of novel SAGs***

20 The novel superantigens were identified by searching the *S. pyogenes* M1 genome database at the University of Oklahoma (<http://www.genome.ou.edu/strep.html>) with highly conserved  $\beta 5$  and  $\alpha 4$  regions of streptococcal and staphylococcal superantigens, using a TBlastN search programme.

25 The open reading frames were defined by translating the DNA sequences around the matching regions and aligning the protein sequences to known superantigens using the computer programmes Gap. Multiple alignments and dendrograms were performed with Lineup and Pileup. The FASTA programme was used for searching the SwissProt (Amos Bairoch, Switzerland) and PIR (Protein Identification Resource, 30 USA) protein databases.

The leader sequences of SPE-G and SPE-H were predicted using the SP Scan programme All computer programmes are part of the GCG package (version 8).

*Cloning of smeZ, smeZ-2, spe-g and spe-h.*

Fifty nanograms of *S.pyogenes* M1 (ATCC 700294) or *S.pyogenes* 2035 genomic DNA was used as a template to amplify the smeZ DNA fragment and the smeZ-2 DNA fragment, respectively, by PCR using the primers

- 5 smeZ-forward (TGGGATCCTTAGAAGTAGATAATA) and  
smeZ-reverse (AAGAATTCTTAGGAGTCAATTTTC) and Taq Polymerase (Promega). The primers contain a terminal tag with the restriction enzyme recognition sequences BamHI and EcoRI, respectively. The amplified DNA fragment, encoding the mature protein without the leader sequence (Kamezawa et al, 1997 Infect. Immun. 65  
10 no9:38281-33) was cloned into a T-tailed pBlueScript SKII vector (Stratagene).

- Spe-g and spe-h were cloned in a similiar approach, using the primers spe-g-fw (CTGGATCCGATGAAAATTTAAAAGATTTAA) and spe-g-rev (AAGAATTCGGGGGGGAGAATAG), and primers spe-h-fw  
15 (TTGGATCCAATTCTTATAATACAACC) and spe-h-rev (AAAAGCTTTTAGCTGATTGACAC), respectively.

- The DNA sequences of the subcloned toxin genes were confirmed by the dideoxy chain termination method using a Licor automated DNA sequencer. As the DNA  
20 sequences from the genomic database are all unedited raw data, 3 subclones of every cloning experiment were analyzed to ensure that no Taq polymerase related mutations were introduced.

*Expression and purification of rSMEZ, rSMEZ-2, rSPE-G and rSPE-H.*

- 25 Subcloned smeZ, smeZ-2 and spe-g fragments were cut from pBlueScript SKII vectors, using restriction enzymes BamHI and EcoRI (LifeTech), and cloned into pGEX-2T expression vectors (Pharmacia). Due to an internal EcoRI restriction site within the spe-H gene, the pBlueScript:spe-h subclone was digested with BamHI and HindIII and the spe-h fragment was cloned into a modified pGEX-2T vector that  
30 contains a HindIII 3'cloning site.

- Recombinant SMEZ, rSMEZ-2 and rSPE-H were expressed in *E.coli* DH5 $\alpha$  cells as glutathione-S-transferase (GST) fusion proteins. Cultures were grown at 37° C and induced for 3-4 h after adding 0.2 mM isopropyl- $\beta$ -D-thiogalactopyranoside (IPTG).  
35 GST - SPE-G fusion protein was expressed in cells grown at 28° C.

The GST fusion proteins were purified on glutathione agarose as described previously (Li et al, 1997) and the mature toxins were cleaved off from GST by trypsin digestion. All recombinant toxins, except rSMEZ, were further purified by  
5 two rounds of cation exchange chromatography using carboxy methyl sepharose (Pharmacia). The GST-SMEZ fusion protein was trypsin digested on the GSH-column and the flow through containing the SMEZ was collected.

#### *Gel electrophoresis*

10 All purified recombinant toxins were tested on a 12% SDS-polyacrylamide gel according the procedure of Laemmli. The isoelectric point of the recombinant toxins was determined by isoelectric focusing on a 5.5% polyacrylamide gel using ampholine pH 5-8 (Pharmacia Biotech). The gel was run for 90 min at 1 W constant power.

15

#### *Toxin proliferation assay*

Human peripheral blood lymphocytes (PBL) were purified from blood of a healthy donor by Histopaque Ficoll (Sigma) fractionation. The PBL were incubated in 96-well round bottom microtiter plates at  $10^5$  cells per well with RPMI-10 (RPMI with 10%  
20 fetal calf serum) containing varying dilutions of recombinant toxins. The dilution series was performed in 1:5 steps from a starting concentration of 10 ng/ml of toxin. Pipette tips were changed after each dilution step. After 3 days 0.1  $\mu$ Ci [ $^3$ H]thymidine was added to each well and cells were incubated for another 24 h. Cells were harvested and counted on a scintillation counter.

25

Mouse leukocytes were obtained from spleens of 5 different mouse strains (SJL, B10.M, B10/J, C3H and BALB/C). Splenocytes were washed in DMEM-10, counted in 5% acetic acid and incubated on microtiter plates at  $10^5$  cells per well with DMEM-10 and toxins as described for human PBLs.

30 TcR V $\beta$  analysis.

V $\beta$  enrichment analysis was performed by anchored multiprimer amplification (Hudson et al, 1993, J exp Med 177:175-185). Human PBLs were incubated with 20 pg/ml of recombinant toxin at  $10^6$  cells/ml for 3 d. A two-fold volume expansion of  
35 the culture followed with medium containing 20 ng/ml IL-2. After another 24h,

stimulated and resting cells were harvested and RNA was prepared using Trizol reagent (Life Tech). A 500 bp  $\beta$ -chain DNA probe was obtained by anchored multiprimer PCR as described previously (38), radiolabeled and hybridized to del (36) individual V $\beta$ s and a C $\beta$  DNA region dot blotted on a Nylon membrane. The membrane was analysed on a Molecular Dynamics Storm Phosphor imager using ImageQuant software. Individual V $\beta$ s were expressed as a percentage of all the V $\beta$ s determined by hybridization to the C $\beta$  probe.

#### *Jurkat cell assay*

Jurkat cells (a human T cell line) and LG-2 cells (a human B lymphoblastoid cell line, homozygous for HLA-DR1) were harvested in log phase and resuspended in RPMI-10. One hundred microliter of the cell suspension, containing  $1 \times 10^5$  Jurkat cells and  $2 \times 10^4$  LG-2 cells were mixed with 100  $\mu$ l of varying dilutions of recombinant toxins on 96 well plates. After incubating overnight at 37° C, 100  $\mu$ l aliquots were transferred onto a fresh plate and 100  $\mu$ l ( $1 \times 10^4$ ) of SeI cells (IL-2 dependent murine T cell line) per well were added. After incubating for 24 h, 0.1  $\mu$ Ci [ $^3$ H]thymidine was added to each well and cells were incubated for another 24 h. Cells were harvested and counted on a scintillation counter. As a control, a dilution series of IL-2 was incubated with SeI cells.

#### *Computer aided modelling of protein structures*

Protein structures of SMEZ-2, SPE-G and SPE-H were created on a Silicon Graphics computer using InsightII/Homology software. The superantigens SEA, SEB and SPE-C were used as reference proteins to determine structurally conserved regions (SCRs). Coordinate files for SEA (1ESF), for SEB (1SEB) and for SPE-C (1AN8) were downloaded from the Brookhaven Protein Database. The primary amino acid sequences of the reference proteins and SMEZ-2, SPE-G and SPE-H, respectively, were aligned and coordinates from superimposed SCR's were assigned to the model proteins. The loop regions between the SCRs were generated by random choice. MolScript software (PJ Kraulis, 1991, J App Crystallography 24:946-50) was used for displaying the computer generated images.

#### *Radiolabeling and LG-2 binding experiments*

Recombinant toxin was radioiodinated by the chloramine T method as previously described (by Li et al. 1997). Labeled toxin was separated from free iodine by size



exclusion chromatography using Sephadex G25 (Pharmacia). LG2 cells were used for cell binding experiments, as described (Li et al. 1997). Briefly, cells were harvested, resuspended in RPMI-10 and mixed at  $10^6$  cells/ml with  $^{125}\text{I}$ -tracer toxin (1 ng) and 0.0001 to 10  $\mu\text{g}$  of unlabeled toxin and incubated at  $37^\circ\text{C}$  for 1 h. After  
5 washing with ice cold RPMI-1 the pelleted cells were analyzed in a gamma counter. For zinc binding assays the toxins were incubated in either RPMI-10 alone, in RPMI-10 with 1 mM EDTA or in RPMI-10 with 1mM EDTA, 2 mM  $\text{ZnCl}_2$ .

Scatchard analysis was performed as described by Cunningham et al. (1989). For  
10 competitive binding studies, 1 ng of  $^{125}\text{I}$ -tracer toxin (rSMEZ, rSMES-2, rSPE-G, rSPE-H, rSEA, rSPE-C, or rTSST) was incubated with 0.0001 to 10  $\mu\text{g}$  of unlabeled toxin (rSMEZ, rSMES-2, rSPE-G, rSPE-H, rSEA, rSEB, rSPE-C, and rTSST) for 1h. For SEB inhibition studies, 20 ng of  $^{125}\text{I}$ -rSEB was used as tracer and samples were incubated for 4h.

15

## Results

### *Identification and sequence analysis of superantigens.*

The Oklahoma University *Streptococcus pyogenes* M1 genome database is accessible  
20 via the internet and contains a collection of more than 300 DNA sequence contigs derived from a shot gun plasmid library of the complete *S. pyogenes* M1 genome. The currently available DNA sequences cover about 95% of the total genome. This database was searched with a highly conserved superantigen peptide sequence, using a search program that screens the DNA database for peptide sequences in all  
25 6 possible reading frames. 8 significant matches and predicted the open reading frames (ORFs) were found by aligning translated DNA sequences to complete protein sequences of known SAg.

Five matches gave complete ORFs with significant homology to streptococcal and  
30 staphylococcal superantigens. Three of these ORFs correlate to SPE-C, SSA and the recently described SMEZ (Kamezawa et al. 1997), respectively. The remaining two ORFs could not be correlated to any known protein in the SwissProt and PIR databases. These novel putative superantigen genes were named spe-g and spe-h (see Figs 3 and 4). One ORF could not be generated completely due to its location  
35 close to the end of a contig. The DNA sequence of the missing 5'-end is located on

another contig, and individual contigs have yet to be assembled in the database. However, the available sequence shows an ORF for the 137 COOH-terminal amino acid residues of a putative novel superantigen which could not be found in the existing protein databases. This gene was named spe-j (see Fig. 5).

5

In two cases a complete ORF could not be defined due to several out-of-frame mutations. Although DNA sequencing errors on the unedited DNA sequences cannot be completely ruled out, the high frequency of inserts and deletions probably represent natural mutation events on pseudogenes, which are no longer used.

10

To produce recombinant proteins of SMEZ, SPE-G and SPE-H, individual genes (coding for the mature toxins without leader sequence) were amplified by PCR, and subcloned for DNA sequencing. Both, *Str. pyogenes* M1 and *Str. pyogenes* 2035 genomic DNA were used and individual toxin gene sequences compared between the two strains. The spe-h gene was isolated from M1 strain, but could not be amplified from strain 2035 genomic DNA suggesting a restricted strain specificity for this toxin. The spe-g gene was cloned from both M1 and 2035, and DNA sequence analysis of both genes showed no differences. The full length sme gene was isolated from both strains, but DNA sequence comparison revealed some striking differences. The sme gene of strain 2035 showed nucleotide changes in 36 positions (or 5%) compared to sme from strain M1 (Fig. 1). The deduced protein sequences differed in 17 amino acid residues (or 8.1%). This difference was sufficient to indicate a new gene. This gene was named sme-2, because it is 95% homologous to sme (see Fig. 2).

25

The most significant difference between SMEZ and SMEZ-2 is an exchanged pentapeptide sequence at position 96-100, where the EEPMS sequence of SMEZ is converted to KTSIL in SMEZ2 (Fig. 1). A second cluster is at position 111-112, where an RR dipeptide is exchanged for GK in SMEZ-2. The remaining 10 different residues are spread over almost the entire primary sequence.

30

A revised superantigen family tree, based on primary amino acid sequence homology now shows 3 general subfamilies; group A comprises SPE-C, SPE-J, SPE-G, SMEZ and SMEZ-2, group B comprises SEC1-3, SEB, SSA, SPE-A and SEG and

group C comprises SEA, SEE, SED, SEH and SEI. Two superantigens, TSST and SPE-H do not belong to any one of those subfamilies.

SMEZ, SMEZ-2, SPE-G and SPE-J are most closely related to SPE-C, increasing the  
5 number of this subfamily from 2 to 5 members. SPE-G shows the highest protein  
sequence homology with SPE-C (38.4% identity and 46.6% similarity). The  
homology of SPE-J to SPE-C is even more significant (56% identity and 62%  
similarity), but this comparison is only preliminary due to the missing NH<sub>2</sub>-terminal  
sequence. SMEZ shows 30.9% / 40.7% homology to SPE-C and SMEZ-2 is 92% /  
10 93% homologous to SMEZ.

SPE-H builds a new branch in the family tree and is most closely related to SED,  
showing 25% identity and 37.3% similarity.

15 Multiple alignment of SAg protein sequences (Fig. 1) shows that similarities are  
clustered within structure determining regions, represented by  $\alpha$ 4,  $\alpha$ 5,  $\beta$ 4 and  $\beta$ 5  
regions. This applies to all toxins of the superantigen family (data not shown) and  
explains why superantigens like SPE-C and SEA have very similar overall structures  
despite their rather low sequence identity of 24.4 %.

20

Although SPE-H is less related to SPE-C it shows 2 common features with the "SPE-  
C subfamily": (I) a truncated NH<sub>2</sub>-terminus, lacking the  $\alpha$ 1 region and (II) a primary  
zinc binding motif (H-X-D) at the C-terminus (Fig. 1). It has been shown for several  
superantigens that this motif is involved in a zinc coordinated binding to the  $\beta$ -chain  
25 of HLA-DR1.

25

Fusion proteins of GST-SMEZ, GST-SMEZ-2 and GST-SPE-H were completely  
soluble and gave yields of about 30 mg per liter. The GST-SPE-G fusion was  
insoluble when grown at 37° C, but mostly soluble when expressed in cells growing  
30 at 28° C. Although soluble GST-SPE-G yields were 20-30 mg per liter, solubility  
decreased after cleavage of the fusion protein with trypsin. Soluble rSPE-G was  
achieved by diluting the GST-SPE-G to less than 0.2 mg/ml prior to cleavage. After  
cation exchange chromatography, purified rSPE-G could be stored at about 0.4  
mg/ml.

35

Recombinant SMEZ could not be separated from GST by ion exchange chromatography. Isoelectric focusing revealed that the isoelectric points of the two proteins are too similar to allow separation (data not shown). Therefore, rSMEZ was released from GST by cleaving with trypsin while still bound to the GSH agarose column. Recombinant SMEZ was collected with the flow through.

The purified recombinant toxins were applied to SDS-PAGE and isoelectric focusing (Fig. 6). Each toxin ran as a single band on the SDS PAA gel confirming their purity and their calculated molecular weights of 24.33 (SMEZ), 24.15 (SMEZ-2), 24.63 (SPE-G) and 23.63 (SPE-H) (Fig. 6A). The isoelectric focusing gel (Fig. 6B) shows a significant difference between rSMEZ and rSMEZ-2. Like most other staphylococcal and streptococcal toxins, rSMEZ-2 possesses a slightly basic isoelectric point at pH 7-8, but rSMEZ is acidic with an IEP at pH 6-6.5.

#### 15 *T cell proliferation and V $\beta$ specificity*

To ensure the native conformation of the purified recombinant toxins, a standard [ $^3$ H]thymidine incorporation assay was performed to test for their potency to stimulate peripheral blood lymphocytes (PBLs). All toxins were active on human T cells (Fig. 7). Recombinant SEA, rSEB, rSPE-C and rTSST were included as reference proteins. The mitogenic potency of these toxins was lower than described previously, but is regarded as a more accurate figure. In previous studies, a higher starting concentration of toxin (100 ng/ml) was used and tips were not changed in between dilutions. This led to significant carryover across the whole dilution range. On this occasion, the starting concentration was 10 ng/ml and tips were changed in between dilutions preventing any carryover.

The half maximal response for rSPE-G and rSPE-H was 2 pg/ml and 50 pg/ml, respectively. No activity was detected at less than 0.02 pg/ml and 0.1 pg/ml, respectively. Both toxins are therefore less potent than rSPE-C. Recombinant SMEZ was similar in potency to rSPE-C, with a  $P_{50\%}$  value of 0.08 pg/ml and no detectable proliferation at less than 0.5 fg/ml. Recombinant SMEZ-2 showed the strongest mitogenic potency of all toxins tested or, as far as can be determined, described elsewhere. The  $P_{50\%}$  value was determined at 0.02 pg/ml and rSMEZ-2 was still active at less than 0.1 pg/ml. All  $P_{50\%}$  values are summarized in Table 1.

TABLE 1

POTENCY OF RECOMBINANT TOXINS ON HUMAN AND MOUSE T CELLS.						
PROLIFERATION POTENTIAL P <sub>50%</sub> [pg/ml]						
TOXIN	HUMAN	SJL	B10.M	B10/J	C3H	BALB/C
SEA	0.1	20	12	1.8	19	1000
SEE	0.2	10	12	1.5	50	15
SEB	0.8	7000	80,000	5000	10,000	1000
TSST	0.2	20	1000	1.2	100	10
SPE-C	0.1	>100,000	>100,000	>100,000	>100,000	>100,000
SMEZ	0.08	80	80	100	9000	200
SMEZ-2	0.02	100	15	10	800	18
SPE-G	2	>100,000	>100,000	>100,000	>100,000	>100,000
SPE-H	50	15	800	5000	100	1000

5 Human PBLs and mouse T cells were stimulated with varying amounts of recombinant toxin. The P<sub>50%</sub> value reflects the concentration of recombinant toxin required to induce 50% maximal cell proliferation. No proliferation was detected for rSPE-C and rSPE-G at any concentration tested on murine T cells.

Murine T cells from 5 different mouse strains were tested for their mitogenic response to rSMEZ, rSMEZ-2, rSPE-G and rSPE-H (Table 1). Recombinant SPE-G showed no activity against any of the mouse strains tested. Recombinant SPE-H, rSMEZ and rSMEZ-2 showed varied potency depending on the individual mouse strain. For example, rSMEZ-2 was 500-fold more potent than rSPE-H in the B10/J strain, while rSPE-H was 7.5-fold more active than rSMEZ-2 in the SJL strain.

The most consistently potent toxin on murine T cells was rSMEZ-2 with  $P_{50\%}$  values of 10 pg/ml in B10/J and 800 pg/ml in C3H. Recombinant SMEZ varied between 80 pg/ml in SJL and B10.M and 9000 pg/ml in C3H. The  $P_{50\%}$  value for rSPE-H was between 15 pg/ml in SJL and 5000 pg/ml in B10/J.

TABLE 2

V $\beta$ SPECIFICITY OF RECOMBINANT TOXINS ON HUMAN PBLs.					
PERCENT V $\beta$ ENRICHMENT					
V $\beta$	Resting	SMEZ	SMEZ-2	SPE-G	SPE-H
1.1	0.2	0.3	0.4	1.2	1
2.1	0.4	<u>8.4</u>	1	<u>17.9</u>	<u>8.6</u>
3.2	4.8	3.1	2.5	3	2.4
4.1	3.5	<u>24.8</u>	<u>14.4</u>	<u>11.2</u>	5.2
5.1	6.2	1.4	2.5	5.7	2.2
5.3	5.6	2.2	4.1	4.7	4.1
6.3	3	0.8	2.3	4.7	3.5
6.4	5.4	2.1	5.9	9.6	5.6
6.9	6.9	3.5	9.3	<u>19.1</u>	12.2
7.3	3.5	<u>15.3</u>	7.3	3.2	<u>12.6</u>
7.4	9	13.5	11.7	2.9	6.3
8.1	8.7	<u>20.7</u>	<u>36</u>	4.5	2.4
9.1	0.3	0.05	0	<u>1.2</u>	<u>2.3</u>
12.3	0.8	1.6	2	<u>3.2</u>	2.6
12.5	3	1.2	2	3	2.3
15.1	0.6	0.5	0.7	1.2	0.8
23.1	0.2	0.1	0.3	0.8	<u>1</u>
total	62.1	99.7	102.8	97.1	75.2

Human PBLs were incubated with 20 pg/ml of recombinant toxin for 4d. Relative enrichment of V $\beta$  cDNAs was analyzed from RNA of stimulated and resting PBLs by anchored primer PCR and reverse dot blot to a panel of 17 different V $\beta$  cDNAs.

The values representing the highest V $\beta$  enrichment are underlined.

The human TcR V $\beta$  specificity of the recombinant toxins was determined by multiprimer anchored PCR and dot blot analysis using a panel of 17 human V $\beta$  DNA regions. The V $\beta$  enrichment after stimulation with toxin was compared to the V $\beta$  profile of unstimulated PBLs (Table 2). The sum total of all V $\beta$ s stimulated by rSMEZ, rSMEZ-2 and rSPE-G was close to 100 % suggesting that the V $\beta$ s used in the panel represent all the targeted V $\beta$ s. On the other hand, the total of the V $\beta$ s stimulated by rSPE-H was only 75%. It is therefore likely that rSPE-H also stimulated some less common V $\beta$ s, which are not represented in the panel. The most dramatic response was seen with all toxins, except rSMEZ2, on V $\beta$ 2.1 bearing T cells (21-fold for rSMEZ, 45-fold for rSPE-G and 22-fold for rSPE-H). In contrast, rSMEZ2 gave only a 2.5-fold increase of V $\beta$ 2.1 T-cells. SPE-G also targeted V $\beta$ 4.1, V $\beta$ 6.9, V $\beta$ 9.1 and V $\beta$ 12.3 (3-4 fold). A moderate enrichment of V $\beta$ 12.6, V $\beta$ 9.1 and V $\beta$ 23.1 (4-8 fold) was observed with rSPE-H. Both, rSMEZ and rSMEZ2, targeted V $\beta$ 4.1 and V $\beta$ 8.1 with similar efficiency (3-7-fold). This finding is of particular interest, because V $\beta$ 8.1 activity had been found in some, but not all *Str. pyogenes* culture supernatants and in crude preparations of SPE-A and SPE-C. Moreover, SPE-B has often been claimed to have V $\beta$ 8 specific activity, but has since been shown to be a contaminant previously called SpeX. The ability of rSMEZ and rSMEZ-2 to stimulate the V $\beta$ 8.1 Jurkat cell line was tested (Fig. 8) Recombinant SMEZ was less potent than the control toxin (rSEE), showing a half maximal response of 0.2 ng/ml, compared to 0.08 ng/ml with rSEE, but rSMEZ-2 was more potent than rSEE (0.02 ng/ml). No proliferation activity was observed with the negative control toxin rSEA.

#### 25 *MHC class II binding*

To determine if there were significant structural differences, the protein structures of SMEZ-2, SPE-G and SPE-H were modelled onto the superimposed structurally conserved regions of SEA, SEB and SPE-C. The models showed that in all three proteins, the 2 amino acid side chains of the COOH-terminal primary zinc binding motif are in close proximity to a third potential zinc ligand to build a zinc binding site, similar to the zinc binding site observed in SEA and SPE-C.

The zinc binding residues in SPE-C are H167, H201, D203, and it is thought that H81 from the HLA-DR1  $\beta$ -chain binds to the same zinc cation to form a regular tetrahedral complex. The two ligands of the primary zinc binding motif, H201 and



D203, are located on the  $\beta$ 12 strand, which is part of the  $\beta$ -grasp motif, a common structural domain of superantigens. The third ligand, H167, comes from the  $\beta$ 10 strand (Roussel et al. 1997).

- 5 In the model of SPE-G three potential zinc binding ligands (H167, H202 and D204) are located at corresponding positions. In the SMEZ-2 and the SPE-H models, the two corresponding  $\beta$ 12 residues are H202, D204 and H198, D200, respectively. The third ligand in SPE-H (D160) and in SMEZ-2 (H162) comes from the  $\beta$ 9 strand and is most similar to H187 in SEA. It has been shown from crystal structures that H167  
10 of SPE-C and H187 of SEA are spatially and geometrically equivalent sites (Scad et al. 1997, Embo J 14 no 14:3292-301; Roussel et al. 1997).

- All superantigens examined so far, except SPE-C, bind to a conserved motif in the MHC class II  $\alpha$ 1-domain. In SEB and TSST, hydrophobic residues on the loop  
15 between the  $\beta$ 1 and  $\beta$ 2 strand project into a hydrophobic depression in the MHCII  $\alpha$ 1-domain. This loop region has changed its character in SPE-C, where the hydrophobic residues ( F44, L45, Y46 and F47 in SEB) are substituted by the less hydrophobic residues T33, T34 and H35. A comparison of this region on the computer generated models revealed that the generic HLA-DR1  $\alpha$ -chain binding site  
20 might also be missing. As the loop regions are generated by random choice, no conclusions can be drawn from their conformation in the models. However, in none of the three models does the  $\beta$ 1- $\beta$ 2-loop have the required hydrophobic features observed in SEB and TSST Swaminathan, S. *et al.*, *Nature* 359, No. 6398:801-6 (1992), Acharya *et al.*, *Nature* 367, No. 6458: 94-7 (1994). The residues are I25, D26,  
25 F27, K28, T29 and S30 in SMEZ-2, T31, T32, N33, S34 in SPE-G and K28, N29, S30, P31, D32, I33, V34 and T35 in SPE-H.

- SMEZ-2 differs from SMEZ in only 17 amino acids. In the model of SMEZ-2 with the position of those 17 residues, most of the exchanges are located on loop regions,  
30 most significantly on the  $\beta$ 5- $\beta$ 6 loop with 5 consecutive residues replaced. The potential zinc binding site and the  $\beta$ 1- $\beta$ 2 loop are not affected by the replaced amino acids.

- The TcR V $\beta$  specificity differs between SMEZ and SMEZ-2 by one V $\beta$ . SMEZ strongly  
35 stimulates V $\beta$ 2 T cells, but SMEZ-2 does not (Table 2). One or more of the 17

exchanged residues in SMEZ/SMEZ-2 may therefore be directly involved in TcR binding. The exact position of the TcR binding site can not be predicted from the model as several regions have been implicated in TcR binding for different toxins. Crystal structures of SEC2 and SEC3, complexed with a TcR  $\beta$ -chain indicated the  
5 direct role of several residues located on  $\alpha$ 2, the  $\beta$ 2- $\beta$ 3 loop, the  $\beta$ 4- $\beta$ 5 loop and  $\alpha$ 4 (Fields et al. 1996 Nature 384 no 6605:188-92). On the other hand, binding of TSST to the TcR involves residues from  $\alpha$ 4, the  $\beta$ 7- $\beta$ 8 loop and the  $\alpha$ 4- $\beta$ 9 loop (Acharya et al. 1994, Nature 367 no 6548:94-7). The SMEZ-2 model shows 3 residues, which may contribute to TcR binding. In SMEZ, Lys is exchanged for Glu at position 80  
10 and Thr is exchanged for Ile at position 84, both on the  $\beta$ 4- $\beta$ 5 loop. On the COOH-terminal end of the  $\alpha$ 4 helix, Ala is replaced by Ser at position 143.

The results from the computer modelled protein structures suggest that all 4 toxins, SMEZ, SMEZ-2, SPE-G and SPE-H, might bind to the HLA-DR1  $\beta$ -chain in a zinc  
15 dependent fashion, similar to SEA and SPE-C, but might not be able to interact with the HLA-DR1  $\alpha$ -site, a situation that has so far only been observed with SPE-C (Roussel et al. 1997; Li et al. 1997).

To find out whether or not zinc is required for binding of the toxins to MHC class II, a binding assay was performed using human LG-2 cells (which are MHC class II  
20 expressing cells homozygous for HLA-DR1). Direct binding of  $^{125}$ I-labeled toxins was completely abolished in the presence of 1 mM EDTA (Fig. 9, Table 3). When 2 mM  $\text{ZnCl}_2$  was added, binding to the LG-2 cells could be restored completely. These results show that the toxins bind in a zinc dependent mode, most likely to the HLA-  
25 DR1  $\beta$ -chain similar to SEA and SPE-C. However, it does yet not exclude the possibility of an additional binding to the HLA-DR1  $\alpha$ -chain.

TABLE 3

BINDING AFFINITIES AND ZINC DEPENDENCIES FOR SUPERANTIGENS TO HUMAN CLASS II		
TOXIN	MHC CLASS II BINDING kd [nM]	ZINC DEPENDENCY
SEA	36/1000	++
SEB	340	-
TSST	130	-
SPE-C	70	++
SMEZ	65/1000	++
SMEZ-2	25/1000	++
SPE-G	16/1000	++
SPE-H	37/2000	++

The binding affinities of the toxins to MHC class II were determined by Scatchard analysis using LG-2 cells. Zinc dependency was determined by binding of recombinant toxins to LG-2 cells in the presence and absence of EDTA, as described in the Materials and Methods section.

5

The biphasic binding of SEA to HLA-DR1 can be deduced from Scatchard analysis. It shows that SEA possesses a high affinity binding site of 36 nM (which is the zinc dependent  $\beta$ -chain binding site) and a low affinity binding site of 1  $\mu$ M ( $\alpha$ -chain binding site). On the other hand, only one binding site for HLA-DR1 was deduced from Scatchard analysis with SEB, TSST and SPE-C, respectively (Table 3).

10

Therefore, Scatchard analysis was performed with radiolabeled rSMEZ, rSMEZ-2, rSPE-G and rSPE-H using LG-2 cells. All four toxins showed multiphasic curves with at least 2 binding sites on LG-2 cells, a high affinity site of 15-65 nM and a low affinity site of 1-2  $\mu$ M (Fig. 10, Table 3).

15

In a further attempt to determine the orientation of the toxins on MHC class II competition binding experiments were performed. The recombinant toxins and reference toxins (rSEA, rSEB, rSPE-C and rTSST) were radiolabeled and tested with excess of unlabeled toxin for binding to LG-2 cells. The results are summarized in Fig. 11. Both, rSEA and rSPE-C, inhibited binding of labeled rSMEZ, rSMEZ-2, rSPE-G and rSPE-H, respectively. However, rSPE-C only partially inhibited binding (50%) of the labeled rSMEZ-2 (Fig. 12). Recombinant SEB did not compete with any other toxin, even at the highest concentration tested. Recombinant TSST was only slightly competitive against  $^{125}\text{I}$ -labeled rSMEZ, rSMEZ-2 and rSPE-G, respectively, and did not inhibit rSPE-H binding at all.

Reciprocal competition experiments were performed. Recombinant SMEZ, rSMEZ-2 and rSPE-H prevented  $^{125}\text{I}$ -rSEA from binding to LG-2 cells. However, only partial competition (50%) was observed even at the highest toxin concentrations (10,000 fold molar excess). Recombinant SPE-G did not prevent binding of  $^{125}\text{I}$ -rSEA and  $^{125}\text{I}$ -rTSST binding was only partially inhibited by rSMEZ, rSMEZ-2 and rSPE-H, but not by rSPE-G. Significantly, none of the toxins inhibited  $^{125}\text{I}$ -rSEB binding, even at the highest concentration tested.

In a further set of competition binding experiments, rSMEZ, rSMEZ-2, rSPE-G and rSPE-H were tested for competition against each other. Both, rSMEZ and rSMEZ-2 competed equally with each other and also prevented binding of labeled rSPE-G and rSPE-H. In contrast, rSPE-G and rSPE-H did not inhibit any other toxin binding suggesting that these toxins had the most restricted subset of MHC class II molecules, which represent specific receptors.

## SECTION B: GENOTYPING

### 30 Genotyping of *S.pyogenes* isolates

Purified genomic DNA from all *Str. Pyogenes* isolates was used for PCR with specific primers for the smeZ, spe-g and spe-h genes as described above and by Proft (1999). In addition, a primer pair specific to a DNA region encoding the 23S rRNA, oligo 23rRNA forward (GCTATTTCGGAGAGAACCAG) and oligo 23rRNA reverse (CTGAAACATCTAAGTAGCTG) was designed and used for PCR as a positive control.

*Southern blot analysis*

About 5µg of genomic DNA was digested using restriction enzyme HindIII (GIBCO) and loaded onto a 0.7% agarose gel. The DNA was transferred from the gel to a Hybond-N+ nylon membrane (Amersham) as described by Maniatis (1989). A 640 bp DNA fragment of the *smez-2* gene was radiolabeled using the RadPrime Labeling System (GIBCO) and  $\alpha$  <sup>32</sup>P-dCTP (NEN). The nylon blots were hybridized with the radiolabeled probe in 2x SSC, 0.5% SDS, 5x Denhardts overnight at 65°C. After washing twice in 0.2x SSC, 0.1% SDS at 65°C the blots were analysed on a Storm PhosphorImager.

**RESULTS**

PCR based genotyping was performed in order to determine the frequency of the genes *smez*, *spe-g* and *spe-h* in streptococcal isolates (Table 4). The PCR primers for *smez* were designed to anneal with both genes, *semz* and *smez-2*. 103 isolates were collected between 1976 and 1998 from varying sites in patients with varying infections, although the majority were from sore throats. They comprised 94 group A *Streptococcus* (GAS) and 9 non-GAS, which were *S. agalactiae* (group B), *S. equis* (group C) and *Streptococcus spp* (group C). There are 25 distinct M/emm types represented among the GAS isolates, 13 isolates are M non-typable (MNT) and in 2 cases the M type is unknown. The analysis was undertaken blinded to the details of each isolate and 2 duplicate isolates were included (95/31 and 4202) to demonstrate the reproducibility of the testing procedure. The isolates are listed in 2 groups. Group 1 contained isolates collected within a large time frame (1976 to 1996). Group 2 comprised of isolates collected within a short time (1998).

All of the 9 non-GAS isolates (belonging to groups B, C and G) were negative for the tested *sag* genes. The frequencies for *smez*, *spe-g* and *spe-h* within the GAS isolates were 95.6%, 100% and 23.9% respectively. A correlation between a certain M/emm type and the presence of the *spe-h* gene could not be established. The deficiency in this current set was that only 5M/emm types were represented by more than one isolate. The most frequent serotype was M/emm 12 with 13 isolates, from which 7 were positive and 6 were negative for *spe-h* suggesting genetic diversity within the

M/emm12 strain. In contrast, all 12 tested NZ1437/M89 isolates were negative for spe-h.

The high frequencies of smeZ and spe-g is of particular interest as this has not been described for any other streptococcal sag gene thus far. Other spe genes, like speA, speC and ssa are found at much lower frequencies and horizontal gene transfer might explain the varying frequencies of these genes in different strains. In contrast, both smeZ and spe-g were found in virtually all tested GAS isolates. Only 4 GAS isolates (11152, 11070, 94/229 and 11610) tested negative for smeZ. These were PT2612, emm65, M49 and emm57. Southern hybridisation was performed to find out if the negative PCR results were due to lack of the smeZ gene or to lack/alteration of the primer binding site(s). HindIII digested genomic DNA of selected streptococcal isolates was probed with a 640 bp radiolabeled smz-2 PCR fragment (Fig. 13). The smeZ gene is located on a 1953 bp HindIII fragment of about 4kb (fragment B), but not to the SMEZ bearing fragment A (lanes 4, 6, 9, 10). In addition, the smeZ probe bound to a second DNA fragment of about 4.2 kb (fragment C) in isolate 11152 (lane 4). In the M1 reference strain (lane 1) and in isolate 4202 (lane 8) the smeZ probe also bound to fragment B, in addition to fragment A. Fragment B in the M1 strain contains a 180 bp region that shares 97% sequence homology with the 3' end of the smeZ gene. These results suggest that the 4 PCR negative isolates possess a truncated smeZ gene or a smeZ-like sequence, but not a complete smeZ gene.

Table 4

Group 1: Isolates collected between 1976 and 1996									
Strain No.	Group	M/emm	Site	Disease	Rib.DNA	Spe-g	Spe-h	Smez	Vβ8
FP 1943	A	M53	ts	ST	+	+	-	+	-
FP 2658	A	M59	ts	ST	+	+	-	+	-
FP 4223	A	M80	ts	ST	+	+	-	+	+
FP 5417	A	M41	ts	ST	+	+	-	+	+
FP 5847	A	M1	ts	ST	+	+	-	+	+
FP 5971	A	M57	ts	ST	+	+	+	+	-
1/5045	A	M4	ts	ST	+	+	-	+	+
79/1575	A	M1	ts	Tcarriage	+	+	+	+	+
81/3033	A	M12	ts	ST	+	+	+	+	+
82/20	A	M4	sk	ulcer	+	+	-	+	+
82/532	A	M12	ts	ST	+	+	+	+	+
82/675	A	NZ1437 §	ws	wound	+	+	-	+	+
84/141	A	M12	ts	ST	+	+	+	+	+
84/1733	A	M4	ts	ST	+	+	-	+	+
84/781	A	NZ1437 §	ts	ST	+	+	-	+	+
85/1	A	M12	ts	ST	+	+	-	+	+
85/167	A	M12	ts	ST	+	+	+	+	+
85/314	A	NZ1437 §	ws	wound	+	+	-	+	+
85/437	A	M81	ws	inf eczema	+	+	-	+	+
85/722	A	n.d.	?	?	+	+	-	+	-
86/435	A	M4	ts	RF	+	+	-	+	+
87/169	A	M12	ts	ST	+	+	+	+	+
87/19	A	M12	ts	ST	+	+	+	+	+
87/781	A	M12	ts	ST	+	+	-	+	+
88/627	A	M12	sk	wound	+	+	-	+	-
89/22	A	M12	ts	fever	+	+	-	+	+
89/25	A	M12	ur	erysipelas	+	+	+	+	+
89/26	A	M1	ts	AGN	+	+	-	+	+
89/54	A	NZ1437 §	ts	ST	+	+	-	+	+
90/306	A	M5	ear	otornhoea	+	+	-	+	+
90/424	A	M4	ts	ST	+	+	-	+	+
91/542	A	M12	ts	ST	+	+	-	+	+
94/11	A	NZ1437 §	ps	abscess	+	+	-	+	+
94/229	A	M49	hvs	endometr.	+	+	+	-	-
94/330	A	M4	ts	SF	+	+	-	+	+
94/354	A	M12	ts	ST	+	+	-	+	+
94/384	A	M4	sk	wound	+	+	-	+	+
94/712	A	NZ1437 §	ws	cellulitis	+	+	-	+	+
95/127	A	NZ1437 §	bc	cellulitis	+	+	-	+	+

95/31	A	NZ1437 §	ws	abscess	+	+	-	+	+
95/31(2)	A	NZ1437 §	ws	abscess	+	+	-	+	+
95/361	A	NZ1437 §	ps	abscess	+	+	-	+	+
96/1	A	n.d.	?	?	+	+	-	+	+
96/364	A	NZ1437 §	be	burns	+	+	-	+	+
96/551	A	M4	eye	eye infect	+	+	-	+	+
96/610	A	M4	ts	SF	+	+	-	+	+
D21	A	M1	ts	Tcarriage	+	+	-	+	+
RC4063	C	-	ts	ST	+	-	-	-	-
SP9205	C	-	ts	ST	+	-	-	-	-
NI6174	G	-	ts	ST	+	-	-	-	-
NI6192	B	-	ts	ST	+	-	-	-	-
VC4141	G	-	ts	ST	+	-	-	-	-

Group 2: Isolates collected in 1998										
Strain No.	student ID	group	M/emm	site	disease	rib.DNA	spe-g	spe-h	smez	Vβ8
4202 *	3310	A	NZ5118Π	ts	ST	+	+	-	+	+
4202(2)	3310	A	NZ5118Π	ts	ST	+	+	-	+	+
9606	2252	A	MNT	ts	ST	+	+	-	+	-
9639	2184	A	MNT	ts	ST	+	+	+	+	+
9779	3230	A	emm56	ts	ST	+	+	-	+	+
9893	6144	A	PT180	ts	ST	+	+	+	+	+
9894	6564	A	emm59	ts	ST	+	+	-	+	+
10019	6264	A	emm44	ts	ST	+	+	+	+	-
10028	9366	A	emm41	ts	ST	+	+	-	+	+
10134	1880	A	ST4547	ts	ST	+	+	-	+	-
10303	3564	A	emm59	ts	ST	+	+	-	+	-
10307	4850	A	NZ5118Π	ts	ST	+	+	-	+	+
10438	4904	A	ST3018	ts	ST	+	+	-	+	+
10463	TSP	A	emm49	ts	ST	+	+	-	+	-
10649	11510	A	ST2267	ts	ST	+	+	-	+	+
10730	11503	A	MNT	ts	ST	+	+	-	+	-
10742	3374	A	ST809	ts	ST	+	+	-	+	+
10761	3254	A	MNT	ts	ST	+	+	-	+	-
10763	6614	PT 3875	ts	ST	+	+	-	+	-	1078 2
4850	A	MNT	ts	ST	+	+	+	+	+	+
10791	10290	A	MNT	ts	ST	+	+	+	+	+
10792	10308	A	MNT	ts	ST	+	+	+	+	-
10846	8854	A	NZ1437 §	ts	ST	+	+	-	+	+



10902	6264	A	NZ5118Π	ts	ST	+	+	-	+	+
10989	5194	A	PT2841	ts	ST	+	+	-	+	-
11070	1434	A	emm65	ts	ST	+	+	+	-	-
11072	1880	A	ST4547	ts	ST	+	+	-	+	-
11083	4538	A	MNT	ts	ST	+	+	-	+	-
11093	9791	A	MNT	ts	ST	+	+	+	+	+
11152	2030	A	PT2612	ts	ST	+	+	+	-	-
11222	4928	A	NZ5118Π	ts	ST	+	+	+	+	+
11227	8854	A	emm14	ts	ST	+	+	-	+	-
11244	2252	A	ST4547	ts	ST	+	+	-	+	-
11276	4524	A	MNT	ts	ST	+	+	-	+	-
11299	2950	A	emm80	ts	ST	+	+	-	+	+
11574	3186	A	ST809	ts	ST	+	+	-	+	+
11580	3280	A	emm53	ts	ST	+	+	-	+	-
11610	2424	A	emm57	ts	ST	+	+	+	-	-
11646	1880	A	ST4547	ts	ST	+	+	-	+	-
11681	3564	A	emm12	ts	ST	+	+	-	+	+
11686	5528	A	PT5757	ts	ST	+	+	-	+	+
11745	12397	A	emm59	ts	ST	+	+	-	+	-
11789	1568	A	MNT	ts	ST	+	+	-	+	-
11802	3266	A	MNT	ts	ST	+	+	-	+	-
11869	2950	A	ST4547	ts	ST	+	+	-	+	-
11961	4916	A	MNT	ts	ST	+	+	-	+	-
12015	12373	A	emm59	ts	ST	+	+	+	+	-
7625	8215	B	-	ts	ST	+	-	-	-	-
8011	3238	B	-	ts	ST	+	-	-	-	-
10388	1653	G	-	ts	ST	+	-	-	-	-
O12633	5395	B	-	ts	ST	+	-	-	-	-

**Table 4:** Genotyping of streptococcal isolates. The isolates were collected between 1976 and 1996 (group 1) and in 1998 (group 2) from patients with varying diseases. The results are based on PCR analysis using purified genomic DNA and specific primers for each of the sag genes.

The non Gas are: B, *S. agalactiae*; C, *S. equis*; G, *Streptococcus spp.*

MNT, M non typable: ts, throat site; ws, wound site; sk, skin; ps, pus site; hvs, high vaginal site; bc, blood culture; ST, sore throat; SF, scarlet fever; RF, rheumatic fever; AGN, acute glomerulonephritis; T carriage, throat carriage.

\* and |, duplicate isolates; §, recently assigned as M89; Π, recently assigned as M92.

#### INDUSTRIAL APPLICATION

5

The superantigens of the invention, polynucleotides which encode them and antibodies which bind them have numerous applications. A number of these are discussed above (including *Streptococci* subtyping, diagnostic applications and therapeutic applications) but it will be appreciated that these are but examples.

10 Other applications will present themselves to those skilled in the art and are in no way excluded from the scope of the invention.

It will also be appreciated that the foregoing examples are illustrations of the invention. The invention may be carried out with the numerous variations and  
15 modifications as will be apparent to those skilled in the art. For example, a native superantigen may be replaced by a synthetic superantigen with on or more deletions, insertions and/or substitutions relative to the corresponding natural superantigen, provided that the superantigen activity is retained. Likewise there are many variations in the way in which the invention can be used in other aspects  
20 of it.

#### REFERENCES

Marrack, P., and J. Kappler. 1990. The staphylococcal enterotoxins and their  
25 relatives. *Science* 248:705-711.

Huber, B.T., P.N. Hsu, and N. Sutkowski. 1996. Virus-encoded superantigens. *Microbiol. Rev.* 60, no. 3:473-82.

30 Alouf, J.E., H. Knoell, and W. Koehler. 1991. The family of mitogenic, shock-inducing and superantigenic toxins from staphylococci and streptococci. Sourcebook of bacterial protein toxins., eds. J.E. Alouf and J.H. Freer. Academic Press, San Diego. 367-414 pp.

- Betley, M.J., D.W. Borst, and L.B. Regassa. 1992. Staphylococcal enterotoxins, toxic shock syndrome toxin and streptococcal exotoxins: a comparative study of their molecular biology. *Chem. Immunol.* 55:1-35.
- 5 Ren, K., J.D. Bannan, V. Pancholi, A.L. Cheung, J.C. Robbins, V.A. Fischetti, and J.B. Zabriskie. 1994. Characterization and biological properties of a new staphylococcal exotoxin. *J. Exp. Med.* 180, no. 5:1675-83.
- Munson, S.H., M.T. Tremaine, M.J. Betley, and R.A. Welch. 1998. Identification and  
10 Characterization Of Staphylococcal Enterotoxin Types G and I From *Staphylococcus Aureus*. *Infect. Immun.* 66, no. 7:3337-3348.
- Herman, A., J.W. Kappler, P. Marrack, and A.M. Pullen. 1991. Superantigens: mechanism of T-cell stimulation and role in immune responses. *Annu. Rev. Immunol.*  
15 9:745-772.
- Janeway, C.J., J. Yagi, P.J. Conrad, M.E. Katz, B. Jones, S. Vroegop, and S. Buxser. 1989. T-cell responses to Mls and to bacterial proteins that mimic its behavior. *Immunol. Rev.* 107:61-68.  
20
- Fast, D.J., P.M. Schlievert, and R.D. Nelson. 1989. Toxic shock syndrome-associated staphylococcal and streptococcal pyrogenic toxins are potent inducers of tumor necrosis factor production. *Infect. Immun.* 57, no. 1:291-4.
- 25 Kotzin, B.L., D.Y. Leung, J. Kappler, and P. Marrack. 1993. Superantigens and their potential role in human disease. *Adv. Immunol.* 54, no. 99:99-166.
- Bohach, G.A., D.J. Fast, R.D. Nelson, and P.M. Schlievert. 1990. Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related  
30 illnesses. *Crit. Rev. Microbiol.* 17, no. 4:251-72.
- Weeks, C.R., and J.J. Ferretti. 1986. Nucleotide Sequence of the Type A Streptococcal Exotoxin (Erythrogenic Toxin) Gene from *Streptococcus pyogenes* Bacteriophage T12. *Infect. Immun.* 52:144-150.

- Goshorn, S.C., G.A. Bohach, and P.M. Schlievert. 1988. Cloning and characterization of the gene, speC, for pyrogenic exotoxin type C from *Streptococcus pyogenes*. *Mol. Gen. Genet.* 212, no. 1:66-70.
- 5 Mollick, J.A., G.G. Miller, J.M. Musser, R.G. Cook, D. Grossman, and R.R. Rich. 1993. A novel superantigen isolated from pathogenic strains of *Streptococcus pyogenes* with aminoterminal homology to staphylococcal enterotoxins B and C. *J. Clin. Invest.* 92, no. 2:710-9.
- 10 Van Den Busche, R.A., J.D. Lyon, and G.A. Bohach. 1993. Molecular evolution of the staphylococcal and streptococcal pyrogenic toxin gene family. *Mol. Phylogenet. Evol.* 2:281-292.
- Dellabona, P., J. Peccoud, J. Kappler, P. Marrack, C. Benoist, and D. Mathis. 1990.
- 15 Superantigens interact with MHC class II molecules outside of the antigen groove. *Cell* 62, no. 6:1115-21.
- Fraser, J.D. 1989. High-affinity binding of staphylococcal enterotoxins A and B to HLA-DR. *Nature* 339, no. 6221:221-3.
- 20
- Fleischer, B., and H. Schrezenmeier. 1988. T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. *J. Exp. Med.* 167, no. 5:1697-707.
- 25
- Mollick, J.A., R.G. Cook, and R.R. Rich. 1989. Class II MHC molecules are specific receptors for staphylococcus enterotoxin A. *Science* 244, no. 4906:817-20.
- Schad, E.M., I. Zaitseva, V.N. Zaitsev, M. Dohlsten, T. Kalland, P.M. Schlievert, D.H.
- 30 Ohlendorf, and L.A. Svensson. 1995. Crystal structure of the superantigen staphylococcal enterotoxin type A. *EMBO J.* 14, no. 14:3292-301.
- Swaminathan, S., W. Furey, J. Pletcher, and M. Sax. 1992. Crystal structure of staphylococcal enterotoxin B, a superantigen. *Nature* 359, no. 6398:801-6.

- Papageorgiou, A.C., K.R. Acharya, R. Shapiro, E.F. Passalacqua, R.D. Brehm, and H.S. Tranter. 1995. Crystal structure of the superantigen enterotoxin C2 from *Staphylococcus aureus* reveals a zinc-binding site. *Structure* 3, no. 8:769-79.
- 5 Sundstrom, M., L. Abrahmsen, P. Antonsson, K. Mehindate, W. Mourad, and M. Dohlsten. 1996. The crystal structure of staphylococcal enterotoxin type D reveals Zn<sup>2+</sup>-mediated homodimerization. *EMBO J.* 15, no. 24:6832-40.
- Acharya, K.R., E.F. Passalacqua, E.Y. Jones, K. Harlos, D.I. Stuart, R.D. Brehm, and  
10 H.S. Tranter. 1994. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. *Nature* 367, no. 6458:94-7.
- Roussel, A., B.F. Anderson, H.M. Baker, J.D. Fraser, and E.N. Baker. 1997. Crystal  
15 structure of the streptococcal superantigen SPE-C: dimerization and zinc binding suggest a novel mode of interaction with MHC class II molecules. *Nat. Struct. Biol.* 4, no. 8:635-43.
- Kim, J., R.G. Urban, J.L. Strominger, and D.C. Wiley. 1994. Toxic shock syndrome  
20 toxin-1 complexed with a class II major histocompatibility molecule HLA-DR1. *Science* 266, no. 5192:1870-4.
- Hurley, J.M., R. Shimonkevitz, A. Hanagan, K. Enney, E. Boen, S. Malmstrom, B.L. Kotzin, and M. Matsumura. 1995. Identification of class II major histocompatibility  
25 complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1. *J. Exp. Med.* 181, no. 6:2229-35.
- Seth, A., L.J. Stern, T.H. Ottenhoff, I. Engel, M.J. Owen, J.R. Lamb, R.D. Klausner, and D.C. Wiley. 1994. Binary and ternary complexes between T-cell receptor, class  
30 II MHC and superantigen in vitro. *Source (Bibliographic Citation): Nature* 369, no. 6478:324-7.
- Li, P.L., R.E. Tiedemann, S.L. Moffat, and J.D. Fraser. 1997. The superantigen streptococcal pyrogenic exotoxin C (SPE-C) exhibits a novel mode of action. *J. Exp. Med.* 186, no. 3:375-83.

- Hudson, K.R., R.E. Tiedemann, R.G. Urban, S.C. Lowe, J.L. Strominger, and J.D. Fraser. 1995. Staphylococcal enterotoxin A has two cooperative binding sites on major histocompatibility complex class II. *J. Exp. Med.* 182, no. 3:711-20.
- 5 Kozono, H., D. Parker, J. White, P. Marrack, and J. Kappler. 1995. Multiple binding sites for bacterial superantigens on soluble class II MHC molecules. *Immunity* 3, no. 2:187-96.
- 10 Tiedemann, R.E., and J.D. Fraser. 1996. Cross-linking of MHC class II molecules by staphylococcal enterotoxin A is essential for antigen-presenting cell and T cell activation. *J. Immunol.* 157, no. 9:3958-66.
- Braun, M.A., D. Gerlach, U.F. Hartwig, J.H. Ozegowski, F. Romagne, S. Carrel, W. Kohler, and B. Fleischer. 1993. Stimulation of human T cells by streptococcal
- 15 "superantigen" erythrogenic toxins (scarlet fever toxins). *J. Immunol.* 150, no. 6:2457-66.
- Kline, J.B., and C.M. Collins. 1997. Analysis of the interaction between the bacterial superantigen streptococcal pyrogenic exotoxin A (SpeA) and the human T-cell
- 20 receptor. *Mol. Microbiol.* 24, no. 1:191-202.
- Fleischer, B., A. Necker, C. Leget, B. Malissen, and F. Romagne. 1996. Reactivity of mouse T-cell hybridomas expressing human Vbeta gene segments with staphylococcal and streptococcal superantigens. *Infect. Immun.* 64, no. 3:987-94.
- 25 Toyosaki, T., T. Yoshioka, Y. Tsuruta, T. Yutsudo, M. Iwasaki, and R. Suzuki. 1996. Definition of the mitogenic factor (MF) as a novel streptococcal superantigen that is different from streptococcal pyrogenic exotoxins A, B, and C. *Eur. J. Immunol.* 26, no. 11:2693-701.
- 30 Kamezawa, Y., T. Nakahara, S. Nakano, Y. Abe, J. Nozaki-Renard, and T. Isono. 1997. Streptococcal mitogenic exotoxin Z, a novel acidic superantigenic toxin produced by a T1 strain of *Streptococcus pyogenes*. *Infect. Immun.* 65, no. 9:3828-33.

Hudson, K.R., H. Robinson, and J.D. Fraser. 1993. Two adjacent residues in Staphylococcal enterotoxins A and E determine T cell receptor V beta specificity. *J. Exp. Med.* 177:175-185.

- 5 Kraulis, P.J. 1991. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. *J. Appl. Crystallography* 24:946-950.

Cunningham, B.C., P. Jhurani, P. Ng, and J.A. Wells. 1989. Receptor and Antibody epitopes in human growth hormone identified by homologue scanning mutagenesis.

- 10 *Science* 243:1330-1336.

Fields, B.A., E.L. Malchiodi, H. Li, X. Ysern, C.V. Stauffacher, P.M. Schlievert, K. Karjalainen, and R.A. Mariuzza. 1996. Crystal structure of a T-cell receptor beta-chain complexed with a superantigen [see comments]. *Nature* 384, no. 6605:188-92.

15

Wen, R., G.A. Cole, S. Surman, M.A. Blackman, and D.L. Woodland. 1996. Major histocompatibility complex class II-associated peptides control the presentation of bacterial superantigens to T cells. *J. Exp. Med.* 183, no. 3:1083-92.

- 20 Thibodeau, J., I. Cloutier, P.M. Lavoie, N. Labrecque, W. Mourad, T. Jardetzky, and R.P. Sekaly. 1994. Subsets of HLA-DR1 molecules defined by SEB and TSST-1 binding. *Science* 266, no. 5192:1874-8.

Abe, J., B.L. Kotzin, K. Jujo, M.E. Melish, M.P. Glode, T. Kohsaka, and D.Y. Leung.

- 25 1992. Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. *PNAS* 89, no. 9:4066-70.

Kawasaki, T. 1967. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. *Jpn. J.*

- 30 *Allergol.* 16:178.

Leung, D.Y., R.C. Giorno, L.V. Kazemi, P.A. Flynn, and J.B. Busse. 1995. Evidence for superantigen involvement in cardiovascular injury due to Kawasaki syndrome. *J. Immunol.* 155, no. 10:5018-21.

35

- Cockerill, F.R., R.L. Thompson, J.M. Musser, P.M. Schlievert, J. Talbot, K.E. Holley, W.S. Harmsen, D.M. Ilstrup, P.C. Kohner, M.H. Kim, B. Frankfort, J.M. Manahan, J.M. Steckelberg, F. Roberson, and W.R. Wilson. 1998. Molecular, Serological, and Clinical Features Of 16 Consecutive Cases Of Invasive Streptococcal Disease. *Clin. Infect. Dis.* 26, no. 6:1448-1458.
- 5
- Kapur, V., K.B. Reda, L.L. Li, L.J. Ho, R.R. Rich, and J.M. Musser. 1994. Characterization and distribution of insertion sequence IS1239 in *Streptococcus pyogenes*. *Gene* 150, no. 1:135-40.
- 10
- T. Proft, S.L. Moffatt, C.J. Berkahn, and J.D. Fraser (1999). Identification and characterisation of novel superantigens from *Streptococcus pyogenes*. *Journal of Experimental Medicine* 189, No. 1:89-102.
- 15
- T. Maniatis, E.F. Fritsch, and J. Sambrook. (1989). *Molecular cloning: a laboratory manual*. Cold Spring Harbour Laboratory, Cold Spring Harbour, NY, USA.
- B.A. Roe, S.P. Linn, L. Song, X. Yuan, S. Clifton, M. McShan and J. Ferretti, (1999). *Str. Pyogenes* M1 genome sequencing project at Oklahoma University. Web:
- 20 <http://www.genome.ou.edu>.



**CLAIMS**

1. A superantigen selected from any one of SMEZ-2, SPE-G, SPE-H and SPE-J, or a functionally equivalent variant thereof.
- 5 2. A superantigen which is SMEZ-2 and which has an amino acid sequence of SEQ ID NO. 2, or a functionally equivalent variant thereof.
3. A superantigen which is SPE-G and which has an amino acid sequence of SEQ ID NO. 4, or a functionally equivalent variant thereof.
- 10 4. A superantigen which is SPE-H and which has an amino acid sequence of SEQ ID NO. 6, or a functionally equivalent variant thereof.
5. A superantigen which is SPE-J and which has an amino acid sequence which includes SEQ ID NO. 8, or a functionally equivalent variant thereof.
- 15 6. A polynucleotide comprising a nucleotide sequence encoding SMEZ-2 or a variant thereof as claimed in claim 2.
- 20 7. A polynucleotide according to claim 6 in which said nucleotide sequence is or includes SEQ ID NO. 1.
8. A polynucleotide comprising a nucleotide sequence encoding SPE-G or a variant thereof as claimed in claim 3.
- 25 9. A polynucleotide according to claim 8 in which said nucleotide sequence is or includes SEQ ID NO. 3.
10. A polynucleotide comprising a nucleotide sequence encoding SPE-H or a variant thereof as claimed in claim 4.
- 30 11. A polynucleotide according to claim 10 in which said nucleotide sequence is or includes SEQ ID NO 5.

12. A polynucleotide comprising a nucleotide sequence encoding SPE-J or a variant thereof as claimed in claim 5.

13. A polynucleotide according to claim 12 in which said nucleotide sequence includes SEQ ID NO. 7.

14. A method of subtyping *Streptococci* which includes the step of detecting the presence or absence of a superantigen as claimed in claim 1.

15. A method of subtyping *Streptococci* which includes the step of detecting the presence or absence of a polynucleotide as claimed in any one of claims 6, 8, 10 or 12.

16. A construct which comprises a superantigen or variant thereof as claimed in claim 1 and a cell-targeting molecule.

17. A construct according to claim 16 in which said cell-targeting molecule specifically binds a tumour cell.

18. A construct according to claim 17 in which said cell-targeting molecule is an antibody.

19. A pharmaceutical composition which includes a construct as claimed in claim 16.

20. An antibody which binds superantigen SMEZ-2 as claimed in claim 2.

21. An antibody which binds superantigen SPE-G as claimed in claim 3.

22. An antibody which binds superantigen SPE-H as claimed in claim 4.

23. An antibody which binds superantigen SPE-J as claimed in claim 5.

24. A kit which includes an antibody as claimed in any one of claims 20 to 23.

25. A nucleic acid molecule which hybridises to a polynucleotide of claim 7.

5 26. A nucleic acid molecule which hybridises to a polynucleotide of claim 9.

27. A nucleic acid molecule which hybridises to a polynucleotide of claim 11.

28. A nucleic acid molecule which hybridises to a polynucleotide of claim 13.

10

29. A kit which includes a nucleic acid molecule as claimed in any one of claims 25 to 28.

15

30. A method of diagnosing a disease which is caused or mediated by expression of a superantigen as claimed in claim 1 which includes the step of detecting the presence of said superantigen using an antibody which binds superantigen SMEZ-2, SPE-G, SPE-H or SPE-J, or detecting the presence of a polynucleotide encoding said superantigen using a nucleic acid molecule which hybridises to a polynucleotide comprising a nucleotide sequence encoding SMEZ-2 which is or includes SEQ ID No. 1, a nucleotide sequence encoding SPE-G which is or includes SEQ ID No. 3, a nucleotide sequence encoding SPE-H which is or includes SEQ ID No. 5, or a nucleotide sequence encoding SPE-J which is or includes SEQ ID No. 7.

20

25

1/13  
FIG 1

SMEZ	-----	-----	LEVDNNSLR	NIMSTIVYEV	SDTVIDSKTS	30
SMEZ-2	-----	-----	LEVDNNSLR	NIMSTIVYEV	SDIVIDSKTS	30
SPE-J	-----	-----	-----	-----	-----	
SPE-C	-----	-----	DSKK	DISNVKSDML	YAMTITPYDM	34
SPE-G	-----	-----	DE	NLKDLKRSR	FAMNITPCDY	32
SPE-H	-----	-----	NSYN	TTNRHMLESL	YKHDSNLIEA	34
SEA	SEKSEEINE	KDLRKKSELQ	GAALGNLQKI	YANEKAKTE	NKESHDQFLQ	49

 $\alpha 2$  $\beta 1$ 

SMEZ	ENLVTKKLDV	RDARDFINS	EMDEYAAND	KDGRILAMES	VFEDWNLSE	80
SMEZ-2	ENLVTKKLDV	RDARDFINS	EMDEYAAND	KTGRILAVES	VFEDWNLSE	80
SPE-J	-----	-----	-----	-----	-----	6
SPE-C	ETLNIDTQKY	RG.NYYISS	EMSYEASQRE	KRDDVDVVEG	LF....MILN	79
SPE-G	NSIHINTKQK	RSECILYVDS	IVSLGITDQS	IKGRVDVVEG	LF....YVFS	78
SPE-H	TS.HML..KY	.SVKXNLSV	FFEKDWISQE	FKDKDUIYA	PSAQEVCE..	78
SEA	ETILFKGFFT	NHSWYNLLV	DFDSKDIDVK	YKGRVILYG	AYYGYQCAGG	99

 $\beta 2$  $\beta 3$  $\alpha 3$  $\beta 4$ 

SMEZ	GKVIAM.TY	GMPPYQEE..	PMSKNIEV	WINRRQIPVE	YQSTSTRTT	127
SMEZ-2	GKVIAM.TY	GMPPYQKT..	SILKNIEV	WINRRQISVE	YQSTSTRTT	127
SPE-J	RYDVYI.IY	GVPSVNSN.	SENSRIVG	LIDGVQOKTL	INPIKIDPI	54
SPE-C	SHTGEY.IY	GVPAQN.N.	KVNERLLG	FLSGESQQNL	NKKIILNDI	126
SPE-G	PPYVDN.IY	GVKHSNQG.	NKSLQFVGD	NQDGRITYLE	SEAVRIKQK	126
SPE-H	CPGKRTEAF	GMILTNSER.	KEIRVEVGV	WDKSKQQ..E	PMF TWRPK	124
SEA	TPNKTACMY	GVVLDHNNRL	TEERKVEIQE	WLD RQNTVE	LETVKTRKN	149

 $\beta 5$  $\beta 6$  $\beta 7$  $\beta 8$ 

SMEZ	VTAOEDDURV	RRLISQHQ	SSGSSYKSC	KVVFHNDNS	DKYSLDIEYV	177
SMEZ-2	VTAOEDDURV	RRLIAQHQL	SSGSSYKSC	KVVFHNDNS	DKYSLDIEYV	177
SPE-J	FTIOEDDRI	QYEMQTYRI	DPNSEMIKG	QPEIAINGNK	.HESFNAYDA	103
SPE-C	VTFOEDDRI	RVLMDNYRI	DATSPYVSG	RIEIGTRDGK	.HEQIDMDS	175
SPE-G	FTLOEDDRI	RFLMEKXNI	DSRSRYTSC	STFLAKDSK	.HYEVDIANK	175
SPE-H	VTAOEDDURV	RLLIKKEDI	NNR..EQKY	SKGTVALDLN	SGKDIFDLY	172
SEA	VTVOEDDLQA	RVLQEKQNL	NSOVFDGKV	QRGLIVFHTS	TEPSVNYDLF	199

 $\beta 8$  $\alpha 4$  $\beta 9$  $\beta 10$ 

SMEZ	..GYRDKESI	ERVYKRI	RSP	NIDKIGHLDL	EIDS	209
SMEZ-2	..GYRDKESI	ERVYKRI	RSP	NIDKIGHLDL	EIDS	209
SPE-J	TSS..STRSDI	ERKVKRI	RTI	NMKDFSHPDI	YVWK	137
SPE-C	PNE.GTRSDI	ERKVKRI	RDI	NMKNFHPDI	YVWK	208
SPE-G	DDKLLSRDSI	ERVYKRI	RIF	NSEEIHPDI	YVWK	210
SPE-H	YFGNGDFNSM	LRIYNSN	ERI	DSTQFHEVDV	SIS	204
SEA	GAQGQNSNTL	LRIYNSN	RTI	ENSENMHIDI	YVYTS	233

 $\alpha 5$  $\beta 11$  $\beta 12$

FIG 2

10 30 50  
ATGAAAAAAACAAAACCTTATTTTTCTTTTACTTCAATATTCATTGCAATAATTTCTCGT  
M K K T K L I F S F T S I F I A I I S R

70 90 110  
CCTGTGTTTGGATTAGAAGTAGATAATAATCCCTTCTAAGGAATATCTATAGTACGATT  
P V F G L E V D N N S L L R N I Y S T I

130 150 170  
GTATATGAATATTCAGATATAGTAATTGATTTTAAAACCAGTCATAACTTAGTGACTAAG  
V Y E Y S D I V I D F K T S H N L V T K

190 210 230  
AAACTTCATGTTAGAGATGCTAGAGATTTCTTTTAACTCCGAAATGGACGAATATGCA  
K L D V R D A R D F F I N S E M D E Y A

250 270 290  
GCCAATGATTTTAAAACCTGGAGATAAAATAGCTGTGTTCTCCGTCCCATTTGATTGGAAC  
A N D F K T G D K I A V F S V P F D W N

310 330 350  
TATTTATCAAAAGGAAAAGTCACAGCATATACCTATGGTGAATAACACCCTACCAAAAA  
Y L S K G K V T A Y T Y G G I T P Y Q K

370 390 410  
ACTTCAATACCTAAAAATatCCCTGTAAATTTATGGattaatGgAAAGcagatCTCTgtT  
T S I P K N I P V N L W I N G K Q I S V

430 450 470  
CcTtaCaaCGAAATATCaaCTAACAAAACAacaGTTACAGCTCAAGAAAttgatCTAAAG  
P Y N E I S T N K T T V T A Q E I D L K

490 510 530  
GTTAGAAAATTTTAAATAGCACAACATCAATTATATCTTCTGTTCTAGCTACAAAAGT  
V R K F L I A Q H Q L Y S S G S S Y K S

550 570 590  
GGTAGACTGGTTTTTCATACAAATGATAATTCAGATAAATATCTTTTCgatacTTTTctat  
G R L V F H T N D N S D K Y S F D L F Y

610 630 650  
gtagGATATAGAGATAAAGAAAGTATCTTTAAAGTATACAAAGACAATAAATCTTTCAAT  
V G Y R D K E S I F K V Y K D N K S F N

670 690  
ATAGATAAAATGGGCATTTAGATATAGAAATTGACTCCTAA  
I D K I G H L D I E I D S \*

SPE-G

3/13

FIG 3

10 30 50  
ATGAAAACAAACATTTTGACAATTATCATATTATCATGTGTTTTAGCTATGGAAGTCAA  
M K T N I L T I I I L S C V F S Y G S Q

70 90 110  
TTAGCTTATGCAGATGAAAATTTAAAAGATTAAAAAGAAGTTAAGATTTCCTATAAT  
L A Y A D E N L K D L K R S L R F A Y N

130 150 170  
ATTACCCCATGCGATTATGAAAATGTAGAAATTGCATTTGTTACTACAAATAGCATAACAT  
I T P C D Y E N V E I A F V T T N S I H

190 210 230  
ATTAATACTAAACAAAAAGATCGGAATGTATTCTTTATGTTGATTCTATTGTATCTTTA  
I N T K Q K R S E C I L Y V D S I V S L

250 270 290  
GGCATTACTGATCAGTTTATAAAAGGGGATAAGGTCGATGTTTTTGGTCTCCCTTATAAT  
G I T D Q F I K G D K V D V F G L P Y N

310 330 350  
TTTTCCCCACCTTATGTAGATAATATTTATGGTGGTATTGTAAAACATTCTGAATCAAGGA  
F S P P Y V D N I Y G G I V K H S N Q G

370 390 410  
AATAAATCATTACAGTTTGTAGGAATTTTAAATCAAGATGGGAAAGAACTTATTTGCC  
N K S L Q F V G I L N Q D G K E T Y L P

430 450 470  
TctgAGGCTGTTCGCATAAAAAAGAAACAGTTTACTTTACAGGAATtgATTTTAAATA  
S E A V R I K K K Q F T L Q E F D F K I

490 510 530  
AGAAAATTTCTAATGGAAAAATACAATATCTATGATTCTGGAATCGCGTTATACATCGGGG  
R K F L M E K Y N I Y D S E S R Y T S G

550 570 590  
AGCCTTTTCTTGCTACTAAAGATAGTAAACATTATGAAGTTGATTTATTTAATAAGGAT  
S L F L A T K D S K H Y E V D L F N K D

610 630 650  
GATAAGCTTTTAAGTCGAGACAGTTTCTTTAAAAGGTATAAAGATAATAAGATTTTAAAT  
D K L L S R D S F F K R Y K D N K I F N

670 690  
AGTGAAGAAATTAGTCATTTTGATATCTACTTAAAAACGCACTAG  
S E E I S H F D I Y L K T H \*

SPE-H

4/13

FIG 4

10 30 50  
ATGAGATATAATTGTCGCTACTCACATATTGATAAGAAAATCTACAGCATGATTATATGT  
M R Y N C R Y S H I D K K I Y S M I I C

70 90 110  
TTGTCATTTCTTTTATATTCCAATGTTGTTCAAGCAAATTCTTATAATACAACCAATAGA  
L S F L L Y S N V V Q A N S Y N T T N R

130 150 170  
CATAATCTAGAATCGCTTTATAAGCATGATTCTAACTTGATTGAAGCCGATAGTATAAAA  
H N L E S L Y K H D S N L I E A D S I K

190 210 230  
AATTCTCCAGATATTGTAACAAGCCATATGTTGAAATATAGTGTCAAGGATAAAAAATTTG  
N S P D I V T S H M L K Y S V K D K N L

250 270 290  
TCAGTTTTTTTTGAGAAAGATTGGATATCACAGGAATTCAAAGATAAAGAAGTAGATATT  
S V F F E K D W I S Q E F K D K E V D I

310 330 350  
TATGCTCTATCTGCACAAGAGGTTTGTGAATGTCCAGGGAAAAGGTATGAAGCGTTtggt  
Y A L S A Q E V C E C P G K R Y E A F G

370 390 410  
GGAATTACATTAACATAATTAGAAAAAAGAAATTAAGTTTCCTGTAAACGtgtGggat  
G I T L T N S E K K E I K V P V N V W D

430 450 470  
AAAAGTAAACAACAGCCGCCTATGTTTATTACAGTCAATAAACCGAAagtaaCCGCTCAG  
K S K Q Q P P M F I T V N K P K V T A Q

490 510 530  
GAAGTGGATATAAAAGTTAGAAAGTTATTGAttaagaaatagATATCTATAATAaccgg  
E V D I K V R K L L I K K Y D I Y N N R

550 570 590  
gaacaaaaataactctaaaggaactgttaccttagATTTAAATTCAGGTAAAGATATTGTT  
E Q K Y S K G T V T L D L N S G K D I V

610 630 650  
TTTGATTGTATTATTTTGGCAATGGAGACTTTAATAGCATGCTAAAAATATATTCCAAT  
F D L Y Y F G N G D F N S M L K I Y S N

670 690 710  
AACGAGAGAATAGactcaactCAATTTTCATGTAGatgTGTCaatcagctaA  
N E R I D S T Q F H V D V S I S \*

SPE-J (partial)

5/13

FIG 5

10 30 50  
CTTCCGTACATATTTACTCGTTATGATGTTTATTATATATATGGTGGGGTTACACCATCA  
L P Y I F T R Y D V Y Y I Y G G V T P S

70 90 110  
GTAAACAGTAATTCGGAAAATAGTAAAATTGTAGGTAATTTACTAATAGATGGAGTCCAG  
V N S N S E N S K I V G N L L I D G V Q

130 150 170  
CAAAAAACACTAATAAATCCCATAAAAAATAGATAAACCTATTTTACGATTCAAGAATTT  
Q K T L I N P I K I D K P I F T I Q E F

190 210 230  
GACTTCAAATCAGACAATATCTTATGCAAACATACAAAATTTATGATCCTAATTCTCCA  
D F K I R Q Y L M Q T Y K I Y D P N S P

250 270 290  
TACATAAAAGGGCAATTAGAAATTGCGATCAATGGCaATAAACATGAAAGTTTAACTTA  
Y I K G Q L E I A I N G N K H E S F N L


310 330 350  
TATGATGCAACCTCATCTAGTACAAGGAGTGATATTTTAAAAAATATAAAGACaATAAG  
Y D A T S S S T R S D I F K K Y K D N K

370 390 410  
ACTATAAATATGAAAGATTTCAGCCATTTTGATATTTACCTTtggACTAAATAA  
T I N M K D F S H F D I Y L W T K \*




6/13

FIG 6




7/13

FIG 7




8/13

FIG 8




9/13

FIG 9




10/13

FIG 10




11/13

FIG 11




12/13

FIG 12



13/13

FIG 13





**RULE 63 (37 C.F.R. 1.63)**  
**DECLARATION AND POWER OF ATTORNEY**  
**FOR PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and I believe I am the original first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

SUPERANTIGENS

the specification of which (check applicable box(s)):

☐ is attached hereto  
☐ was filed on \_\_\_\_\_ as U.S. Application Serial No. \_\_\_\_\_ (Atty Dkt. No.)  
☐ was filed as PCT international application No. PCT/NZ99/00228 on 24 December 1999  
 and (if applicable to U.S. or PCT application) was amended on \_\_\_\_\_

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with 37 C.F.R. 1.56. I hereby claim foreign priority benefits under 35 U.S.C. 119/365 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed or, if no priority is claimed, before the filing date of this application:

Prior Foreign Application(s):

Application Number  
333589

Country  
New Zealand

Day/Month/Year Filed  
24 December 1998

I hereby claim the benefit under 35 U.S.C. §119(e) of any United States provisional application(s) listed below.

Application Number

Filing Date

I hereby claim the benefit under 35 U.S.C. 120/365 of all prior United States and PCT international applications listed above or below and, insofar as the subject matter of each of the claims of this application is not disclosed in such prior applications in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose material information as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior applications and the national or PCT international filing date of this application:

Prior U.S./PCT Application(s):  
 Application Serial No.

Day/Month/Year Filed

Status: patented,  
 pending, abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon. And I hereby appoint NIXON & VANDERHYE P.C., 1100 North Glebe Rd., 8th Floor, Arlington, VA 22201-4714, telephone number (703) 816-4000 (to whom all communications are to be directed), and the following attorneys thereof (or of the same address) individually and collectively my attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith and with the resulting patent: Arthur R. Crawford, 25327; Larry S. Nixon, 25640; Robert A. Vanderhye, 27076; James T. Hosmer, 30184; Robert W. Faris, 31352; Richard G. Besha, 22770; Mark E. Nusbaum, 32348; Michael J. Keenan, 32108; Bryan H. Davidson, 30251; Stanley C. Spooner, 27393; Leonard C. Mitchard, 29009; Duane M. Byers, 33363; Paul J. Henon, 33626; Jeffry H. Nelson, 30481; John R. Lastova, 33149; H. Warren Burnam, Jr., 29366; Thomas E. Byrne, 32205; Mary J. Wilson, 32955; J. Scott Davidson, 33489; Jerry D. Craig, 38026; Alan M. Kagen, 36178; William J. Griffin, 31260.

1. Inventors' Signature: [Signature] Date: 21/06/01  
 Inventor: John D. Fraser New Zealand  
                     (first) MI (last) (citizenship)  
 Residence: (city) Auckland (state/country) NZ New Zealand  
 Post Office Address: Auckland Uniservices Limited, UniServices House, 58 Symonds Street, Auckland  
 (Zip Code) \_\_\_\_\_

2. Inventors' Signature: [Signature] Date: 21/06/01  
 Inventor: Thomas Proft New Zealand  
                     (first) MI (last) (citizenship) PR  
 Residence: (city) Auckland (state/country) NZ New Zealand  
 Post Office Address: Auckland Uniservices Limited, UniServices House, 58 Symonds Street, Auckland  
 (Zip Code) \_\_\_\_\_

FOR ADDITIONAL INVENTORS, check box ☐ and attach sheet with same information and signature and date for each.

WO 00/39159

SEQUENCE LISTING

<110> Auckland UniServices Limited

<120> Superantigens

<130> 25426 MRB

<140>

<141>

<150> NZ 333589

<151> 1998-12-24

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 702

<212> DNA

<213> Streptococcus pyogenes

<220>

<221> CDS

<222> (1)..(699)

<400> 1

atg aaa aaa aca aaa ctt att ttt tct ttt act tca ata ttc att gca 48  
 Met Lys Lys Thr Lys Leu Ile Phe Ser Phe Thr Ser Ile Phe Ile Ala  
 1 5 10 15

ata att tct cgt cct gtg ttt gga tta gaa gta gat aat aat tcc gtt 96  
 Ile Ile Ser Arg Pro Val Phe Gly Leu Glu Val Asp Asn Asn Ser Leu  
 20 25 30

cta agg aat atc tat agt acg att gta tat gaa tat tca gat ata gta 144  
 Leu Arg Asn Ile Tyr Ser Thr Ile Val Tyr Glu Tyr Ser Asp Ile Val  
 35 40 45

att gat ttt aaa acc agt cat aac tta gtg act aag aaa ctt gat gtt 192  
 Ile Asp Phe Lys Thr Ser His Asn Leu Val Thr Lys Lys Leu Asp Val  
 50 55 60

aga gat gct aga gat ttc ttt att aac tcc gaa atg gac gaa tat gca 240  
 Arg Asp Ala Arg Asp Phe Phe Ile Asn Ser Glu Met Asp Glu Tyr Ala  
 65 70 75 80

```

gcc aat gat ttt aaa act gga gat aaa ata gct gtg ttc tcc gtc cca      288
Ala Asn Asp Phe Lys Thr Gly Asp Lys Ile Ala Val Phe Ser Val Pro
           85                      90                      95

ttt gat tgg aac tat tta tca aaa gga aaa gtc aca gca tat acc tat      336
Phe Asp Trp Asn Tyr Leu Ser Lys Gly Lys Val Thr Ala Tyr Thr Tyr
           100                    105                    110

ggg gga ata aca ccc tac caa aaa act tca ata cct aaa aat atc cct      384
Gly Gly Ile Thr Pro Tyr Gln Lys Thr Ser Ile Pro Lys Asn Ile Pro
           115                    120                    125

gtt aat tta tgg att aat gga aag cag atc tct gtt cct tac aac gaa      432
Val Asn Leu Trp Ile Asn Gly Lys Gln Ile Ser Val Pro Tyr Asn Glu
           130                    135                    140

ata tca act aac aaa aca aca gtt aca gct caa gaa att gat cta aag      480
Ile Ser Thr Asn Lys Thr Thr Val Thr Ala Gln Glu Ile Asp Leu Lys
           145                    150                    155                    160

gtt aga aaa ttt tta ata gca caa cat caa tta tat tct tct ggt tct      528
Val Arg Lys Phe Leu Ile Ala Gln His Gln Leu Tyr Ser Ser Gly Ser
           165                    170                    175

agc tac aaa agt ggt aga ctg gtt ttt cat aca aat gat aat tca gat      576
Ser Tyr Lys Ser Gly Arg Leu Val Phe His Thr Asn Asp Asn Ser Asp
           180                    185                    190

aaa tat tct ttc gat ctt ttc tat gta gga tat aga gat aaa gaa agt      624
Lys Tyr Ser Phe Asp Leu Phe Tyr Val Gly Tyr Arg Asp Lys Glu Ser
           195                    200                    205

atc ttt aaa gta tac aaa gac aat aaa tct ttc aat ata gat aaa att      672
Ile Phe Lys Val Tyr Lys Asp Asn Lys Ser Phe Asn Ile Asp Lys Ile
           210                    215                    220

ggg cat tta gat ata gaa att gac tcc taa                                702
Gly His Leu Asp Ile Glu Ile Asp Ser
           225                    230

```

&lt;210&gt; 2

&lt;211&gt; 233

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 2

Met Lys Lys Thr Lys Leu Ile Phe Ser Phe Thr Ser Ile Phe Ile Ala

1	5	10	15
Ile Ile Ser Arg Pro Val Phe Gly Leu Glu Val Asp Asn Asn Ser Leu	20	25	30
Leu Arg Asn Ile Tyr Ser Thr Ile Val Tyr Glu Tyr Ser Asp Ile Val	35	40	45
Ile Asp Phe Lys Thr Ser His Asn Leu Val Thr Lys Lys Leu Asp Val	50	55	60
Arg Asp Ala Arg Asp Phe Phe Ile Asn Ser Glu Met Asp Glu Tyr Ala	65	70	75
Ala Asn Asp Phe Lys Thr Gly Asp Lys Ile Ala Val Phe Ser Val Pro	85	90	95
Phe Asp Trp Asn Tyr Leu Ser Lys Gly Lys Val Thr Ala Tyr Thr Tyr	100	105	110
Gly Gly Ile Thr Pro Tyr Gln Lys Thr Ser Ile Pro Lys Asn Ile Pro	115	120	125
Val Asn Leu Trp Ile Asn Gly Lys Gln Ile Ser Val Pro Tyr Asn Glu	130	135	140
Ile Ser Thr Asn Lys Thr Thr Val Thr Ala Gln Glu Ile Asp Leu Lys	145	150	155
Val Arg Lys Phe Leu Ile Ala Gln His Gln Leu Tyr Ser Ser Gly Ser	165	170	175
Ser Tyr Lys Ser Gly Arg Leu Val Phe His Thr Asn Asp Asn Ser Asp	180	185	190
Lys Tyr Ser Phe Asp Leu Phe Tyr Val Gly Tyr Arg Asp Lys Glu Ser	195	200	205
Ile Phe Lys Val Tyr Lys Asp Asn Lys Ser Phe Asn Ile Asp Lys Ile	210	215	220
Gly His Leu Asp Ile Glu Ile Asp Ser	225	230	

&lt;210&gt; 3

&lt;211&gt; 705

&lt;212&gt; DNA

&lt;213&gt; Streptococcus pyogenes

&lt;220&gt;

&lt;221&gt; CDS

&lt;222&gt; (1)..(702)

&lt;400&gt; 3

```

atg aaa aca aac att ttg aca att atc ata tta tca tgt gtt ttt agc   48
Met Lys Thr Asn Ile Leu Thr Ile Ile Ile Leu Ser Cys Val Phe Ser
   1             5             10             15

tat gga agt caa tta gct tat gca gat gaa aat tta aaa gat tta aaa   96
Tyr Gly Ser Gln Leu Ala Tyr Ala Asp Glu Asn Leu Lys Asp Leu Lys
      20             25             30

aga agt tta aga ttt gcc tat aat att acc cca tgc gat tat gaa aat   144
Arg Ser Leu Arg Phe Ala Tyr Asn Ile Thr Pro Cys Asp Tyr Glu Asn
      35             40             45

gta gaa att gca ttt gtt act aca aat agc ata cat att aat act aaa   192
Val Glu Ile Ala Phe Val Thr Thr Asn Ser Ile His Ile Asn Thr Lys
      50             55             60

caa aaa aga tcg gaa tgt att ctt tat gtt gat tct att gta tct tta   240
Gln Lys Arg Ser Glu Cys Ile Leu Tyr Val Asp Ser Ile Val Ser Leu
      65             70             75             80

ggc att act gat cag ttt ata aaa ggg gat aag gtc gat gtt ttt ggt   288
Gly Ile Thr Asp Gln Phe Ile Lys Gly Asp Lys Val Asp Val Phe Gly
      85             90             95

ctc cct tat aat ttt tcc cca cct tat gta gat aat att tat ggt ggt   336
Leu Pro Tyr Asn Phe Ser Pro Pro Tyr Val Asp Asn Ile Tyr Gly Gly
      100            105            110

att gta aaa cat tcg aat caa gga aat aaa tca tta cag ttt gta gga   384
Ile Val Lys His Ser Asn Gln Gly Asn Lys Ser Leu Gln Phe Val Gly
      115            120            125

att tta aat caa gat ggg aaa gaa act tat ttg ccc tct gag gct gtt   432
Ile Leu Asn Gln Asp Gly Lys Glu Thr Tyr Leu Pro Ser Glu Ala Val
      130            135            140

cgc ata aaa aag aaa cag ttt act tta cag gaa ttt gat ttt aaa ata   480
Arg Ile Lys Lys Lys Gln Phe Thr Leu Gln Glu Phe Asp Phe Lys Ile
      145            150            155            160

```

aga aaa ttt cta atg gaa aaa tac aat atc tat gat tcg gaa tcg cgt 528  
 Arg Lys Phe Leu Met Glu Lys Tyr Asn Ile Tyr Asp Ser Glu Ser Arg  
 165 170 175

tat aca tcg ggg agc ctt ttc ctt gct act aaa gat agt aaa cat tat 576  
 Tyr Thr Ser Gly Ser Leu Phe Leu Ala Thr Lys Asp Ser Lys His Tyr  
 180 185 190

gaa gtt gat tta ttt aat aag gat gat aag ctt tta agt cga gac agt 624  
 Glu Val Asp Leu Phe Asn Lys Asp Asp Lys Leu Leu Ser Arg Asp Ser  
 195 200 205

ttc ttt aaa agg tat aaa gat aat aag att ttt aat agt gaa gaa att 672  
 Phe Phe Lys Arg Tyr Lys Asp Asn Lys Ile Phe Asn Ser Glu Glu Ile  
 210 215 220

agt cat ttt gat atc tac tta aaa acg cac tag 705  
 Ser His Phe Asp Ile Tyr Leu Lys Thr His  
 225 230

<210> 4

<211> 234

<212> PRT

<213> Streptococcus pyogenes

<400> 4

Met Lys Thr Asn Ile Leu Thr Ile Ile Ile Leu Ser Cys Val Phe Ser  
 1 5 10 15

Tyr Gly Ser Gln Leu Ala Tyr Ala Asp Glu Asn Leu Lys Asp Leu Lys  
 20 25 30

Arg Ser Leu Arg Phe Ala Tyr Asn Ile Thr Pro Cys Asp Tyr Glu Asn  
 35 40 45

Val Glu Ile Ala Phe Val Thr Thr Asn Ser Ile His Ile Asn Thr. Lys  
 50 55 60

Gln Lys Arg Ser Glu Cys Ile Leu Tyr Val Asp Ser Ile Val Ser Leu  
 65 70 75 80

Gly Ile Thr Asp Gln Phe Ile Lys Gly Asp Lys Val Asp Val Phe Gly  
 85 90 95

Leu Pro Tyr Asn Phe Ser Pro Pro Tyr Val Asp Asn Ile Tyr Gly Gly  
 100 105 110

Ile Val Lys His Ser Asn Gln Gly Asn Lys Ser Leu Gln Phe Val Gly  
 115 120 125

Ile Leu Asn Gln Asp Gly Lys Glu Thr Tyr Leu Pro Ser Glu Ala Val  
 130 135 140

Arg Ile Lys Lys Lys Gln Phe Thr Leu Gln Glu Phe Asp Phe Lys Ile  
 145 150 155 160

Arg Lys Phe Leu Met Glu Lys Tyr Asn Ile Tyr Asp Ser Glu Ser Arg  
 165 170 175

Tyr Thr Ser Gly Ser Leu Phe Leu Ala Thr Lys Asp Ser Lys His Tyr  
 180 185 190

Glu Val Asp Leu Phe Asn Lys Asp Asp Lys Leu Leu Ser Arg Asp Ser  
 195 200 205

Phe Phe Lys Arg Tyr Lys Asp Asn Lys Ile Phe Asn Ser Glu Glu Ile  
 210 215 220

Ser His Phe Asp Ile Tyr Leu Lys Thr His  
 225 230

<210> 5

<211> 711

<212> DNA

<213> Streptococcus pyogenes

<220>

<221> CDS

<222> (1)..(708)

<400> 5

atg aga tat aat tgt cgc tac tca cat att gat aag aaa atc tac agc 48  
 Met Arg Tyr Asn Cys Arg Tyr Ser His Ile Asp Lys Lys Ile Tyr Ser  
 1 5 10 15

atg att ata tgt ttg tca ttt ctt tta tat tcc aat gtt gtt caa gca 96  
 Met Ile Ile Cys Leu Ser Phe Leu Leu Tyr Ser Asn Val Val Gln Ala  
 20 25 30

aat tct tat aat aca acc aat aga cat aat cta gaa tcg ctt tat aag 144  
 Asn Ser Tyr Asn Thr Thr Asn Arg His Asn Leu Glu Ser Leu Tyr Lys  
 35 40 45

cat gat tct aac ttg att gaa gcc gat agt ata aaa aat tct cca gat 192  
His Asp Ser Asn Leu Ile Glu Ala Asp Ser Ile Lys Asn Ser Pro Asp  
50 55 60

att gta aca agc cat atg ttg aaa tat agt gtc aag gat aaa aat ttg 240  
Ile Val Thr Ser His Met Leu Lys Tyr Ser Val Lys Asp Lys Asn Leu  
65 70 75 80

tca gtt ttt ttt gag aaa gat tgg ata tca cag gaa ttc aaa gat aaa 288  
Ser Val Phe Phe Glu Lys Asp Trp Ile Ser Gln Glu Phe Lys Asp Lys  
85 90 95

gaa gta gat att tat gct cta tct gca caa gag gtt tgt gaa tgt cca 336  
Glu Val Asp Ile Tyr Ala Leu Ser Ala Gln Glu Val Cys Glu Cys Pro  
100 105 110

ggg aaa agg tat gaa gcg ttt ggt gga att aca tta act aat tca gaa 384  
Gly Lys Arg Tyr Glu Ala Phe Gly Gly Ile Thr Leu Thr Asn Ser Glu  
115 120 125

aaa aaa gaa att aaa gtt cct gta aac gtg tgg gat aaa agt aaa caa 432  
Lys Lys Glu Ile Lys Val Pro Val Asn Val Trp Asp Lys Ser Lys Gln  
130 135 140

cag ccg cct atg ttt att aca gtc aat aaa ccg aaa gta acc gct cag 480  
Gln Pro Pro Met Phe Ile Thr Val Asn Lys Pro Lys Val Thr Ala Gln  
145 150 155 160

gaa gtg gat ata aaa gtt aga aag tta ttg att aag aaa tac gat atc 528  
Glu Val Asp Ile Lys Val Arg Lys Leu Leu Ile Lys Lys Tyr Asp Ile  
165 170 175

tat aat aac cgg gaa caa aaa tac tct aaa gga act gtt acc tta gat 576  
Tyr Asn Asn Arg Glu Gln Lys Tyr Ser Lys Gly Thr Val Thr Leu Asp  
180 185 190

tta aat tca ggt aaa gat att gtt ttt gat ttg tat tat ttt ggc aat 624  
Leu Asn Ser Gly Lys Asp Ile Val Phe Asp Leu Tyr Tyr Phe Gly Asn  
195 200 205

gga gac ttt aat agc atg cta aaa ata tat tcc aat aac gag aga ata 672  
Gly Asp Phe Asn Ser Met Leu Lys Ile Tyr Ser Asn Asn Glu Arg Ile  
210 215 220

gac tca act caa ttt cat gta gat gtg tca atc agc taa 711  
Asp Ser Thr Gln Phe His Val Asp Val Ser Ile Ser  
225 230 235



&lt;210&gt; 6

&lt;211&gt; 236

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 6

Met Arg Tyr Asn Cys Arg Tyr Ser His Ile Asp Lys Lys Ile Tyr Ser  
 1 5 10 15

Met Ile Ile Cys Leu Ser Phe Leu Leu Tyr Ser Asn Val Val Gln Ala  
 20 25 30

Asn Ser Tyr Asn Thr Thr Asn Arg His Asn Leu Glu Ser Leu Tyr Lys  
 35 40 45

His Asp Ser Asn Leu Ile Glu Ala Asp Ser Ile Lys Asn Ser Pro Asp  
 50 55 60

Ile Val Thr Ser His Met Leu Lys Tyr Ser Val Lys Asp Lys Asn Leu  
 65 70 75 80

Ser Val Phe Phe Glu Lys Asp Trp Ile Ser Gln Glu Phe Lys Asp Lys  
 85 90 95

Glu Val Asp Ile Tyr Ala Leu Ser Ala Gln Glu Val Cys Glu Cys Pro  
 100 105 110

Gly Lys Arg Tyr Glu Ala Phe Gly Gly Ile Thr Leu Thr Asn Ser Glu  
 115 120 125

Lys Lys Glu Ile Lys Val Pro Val Asn Val Trp Asp Lys Ser Lys Gln  
 130 135 140

Gln Pro Pro Met Phe Ile Thr Val Asn Lys Pro Lys Val Thr Ala Gln  
 145 150 155 160

Glu Val Asp Ile Lys Val Arg Lys Leu Leu Ile Lys Lys Tyr Asp Ile  
 165 170 175

Tyr Asn Asn Arg Glu Gln Lys Tyr Ser Lys Gly Thr Val Thr Leu Asp  
 180 185 190

Leu Asn Ser Gly Lys Asp Ile Val Phe Asp Leu Tyr Tyr Phe Gly Asn  
 195 200 205

Gly Asp Phe Asn Ser Met Leu Lys Ile Tyr Ser Asn Asn Glu Arg Ile  
 210 215 220

Asp Ser Thr Gln Phe His Val Asp Val Ser Ile Ser  
 225 230 235

<210> 7

<211> 414

<212> DNA

<213> Streptococcus pyogenes

<220>

<221> CDS

<222> (1)..(411)

<400> 7

```

ctt ccg tac ata ttt act cgt tat gat gtt tat tat ata tat ggt ggg 48
Leu Pro Tyr Ile Phe Thr Arg Tyr Asp Val Tyr Tyr Ile Tyr Gly Gly
  1             5             10             15

gtt aca cca tca gta aac agt aat tcg gaa aat agt aaa att gta ggt 96
Val Thr Pro Ser Val Asn Ser Asn Ser Glu Asn Ser Lys Ile Val Gly
      20             25             30

aat tta cta ata gat gga gtc cag caa aaa aca cta ata aat ccc ata 144
Asn Leu Leu Ile Asp Gly Val Gln Gln Lys Thr Leu Ile Asn Pro Ile
      35             40             45

aaa ata gat aaa cct att ttt acg att caa gaa ttt gac ttc aaa atc 192
Lys Ile Asp Lys Pro Ile Phe Thr Ile Gln Glu Phe Asp Phe Lys Ile
      50             55             60

aga caa tat ctt atg caa aca tac aaa att tat gat cct aat tct cca 240
Arg Gln Tyr Leu Met Gln Thr Tyr Lys Ile Tyr Asp Pro Asn Ser Pro
      65             70             75             80

tac ata aaa ggg caa tta gaa att gcg atc aat ggc aat aaa cat gaa 288
Tyr Ile Lys Gly Gln Leu Glu Ile Ala Ile Asn Gly Asn Lys His Glu
      85             90             95

agt ttt aac tta tat gat gca acc tca tct agt aca agg agt gat att 336
Ser Phe Asn Leu Tyr Asp Ala Thr Ser Ser Ser Thr Arg Ser Asp Ile
      100            105            110

ttt aaa aaa tat aaa gac aat aag act ata aat atg aaa gat ttc agc 384
Phe Lys Lys Tyr Lys Asp Asn Lys Thr Ile Asn Met Lys Asp Phe Ser
      115            120            125

```

cat ttt gat att tac ctt tgg act aaa taa  
 His Phe Asp Ile Tyr Leu Trp Thr Lys  
 130 135

414

&lt;210&gt; 8

&lt;211&gt; 137

&lt;212&gt; PRT

&lt;213&gt; Streptococcus pyogenes

&lt;400&gt; 8

Leu Pro Tyr Ile Phe Thr Arg Tyr Asp Val Tyr Tyr Ile Tyr Gly Gly  
 1 5 10 15

Val Thr Pro Ser Val Asn Ser Asn Ser Glu Asn Ser Lys Ile Val Gly  
 20 25 30

Asn Leu Leu Ile Asp Gly Val Gln Gln Lys Thr Leu Ile Asn Pro Ile  
 35 40 45

Lys Ile Asp Lys Pro Ile Phe Thr Ile Gln Glu Phe Asp Phe Lys Ile  
 50 55 60

Arg Gln Tyr Leu Met Gln Thr Tyr Lys Ile Tyr Asp Pro Asn Ser Pro  
 65 70 75 80

Tyr Ile Lys Gly Gln Leu Glu Ile Ala Ile Asn Gly Asn Lys His Glu  
 85 90 95

Ser Phe Asn Leu Tyr Asp Ala Thr Ser Ser Ser Thr Arg Ser Asp Ile  
 100 105 110

Phe Lys Lys Tyr Lys Asp Asn Lys Thr Ile Asn Met Lys Asp Phe Ser  
 115 120 125

His Phe Asp Ile Tyr Leu Trp Thr Lys  
 130 135